

FOIA MARKER

This is not a textual record. This is used as an administrative marker by the William J. Clinton Presidential Library Staff.

Collection/Record Group: Clinton Presidential Records
Subgroup/Office of Origin: National AIDS Policy Office
Series/Staff Member: Patsy Fleming
Subseries: National AIDS Strategy

OA/ID Number: 10181
FolderID:

Folder Title:
Invitations 1996-1997 [3]

Stack:	Row:	Section:	Shelf:	Position:
S	66	5	9	2

Withdrawal/Redaction Marker

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
001. resume	[Personally Identifiable Information] [partial] (1 page)	11/11/1996	b(6)

COLLECTION:

Clinton Presidential Records
National AIDS Policy Office
Patsy Fleming (National AIDS Strategy)
OA/Box Number: 10181

FOLDER TITLE:

[Invitations 1996-1997] [3]

2018-0755-F

rs3181

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

- P1 National Security Classified Information [(a)(1) of the PRA]
- P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
- P3 Release would violate a Federal statute [(a)(3) of the PRA]
- P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
- P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
- P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

- b(1) National security classified information [(b)(1) of the FOIA]
- b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
- b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
- b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
- b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
- b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
- b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
- b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]



KREBS Convention Management Services

555 DeHaro Street, Suite 333
San Francisco, CA 94107-2348
(415) 255-1295
Fax (415) 255-2244

FAX MEMO

TO: Richard Sorian
Public Affairs
The Office of National AIDS Policy
(202) 632-1096

FROM: Sheridan Corrie

DATE: January 10, 1997

TOTAL PAGES: 6

Dear Mr. Sorian,

This letter serves to formally request a letter from the Director to be included in the Final Program for the 9th National AIDS Update Conference. Patsy Fleming was able to speak last year at the Conference as well as include a letter in the program, and we would love to include her again this year.

This year's conference offers health care professionals and those directly affected by HIV/AIDS a forum for learning and discussing the latest HIV research, therapy, education and policies. The issues will be covered using a mix of workshops, exhibits and special events. Attached is a Preliminary Program with more details for your reference.

The letter may be one of best wishes, a statement in support of the conference, or a reflection on the current issues related to the epidemic.

Please send the original letter to my attention at the above address for receipt by February 7.

Thank you in advance for your help and quick turn around. Please contact me with any questions.

Sincerely,

Sheridan Corrie

Sheridan Corrie
Project Manager

*Spoke w/ Sheridan
Corrie on
1/14/97
PF declined,
C*



**9TH NATIONAL
AIDS UPDATE
CONFERENCE**

March 18 - 22, 1997

San Francisco Civic Auditorium


Preliminary Program

"Charting a

new course

in an

uncertain environment"



'Me Now'

Z.D., age 36, Immune deficiency, June 1995

Art for Recovery at UCSF/Mount Zion Medical Center

(Marking pen & colored pencil)

Artist's comments: Snake, symbol of life/death (sheds skin). Creativity gives the snake a patchwork of experiences and feelings. The spiral reflects the dance of life—able to attract or repulse specific energies.

1 - 9th National AIDS Update Conference

program goals

This past year marked enormous changes and advances in our understanding and treatment of HIV infection and AIDS. No longer an immediate death sentence, the disease may now be viewed with the hope of long-term chronic management. The goal of this Ninth National AIDS Update Conference is to provide a forum for discussion and dialogue among those who work with and are affected by the epidemic and its new direction. The theme "*Charting a New Course in an Uncertain Environment*" reflects this new and hopeful perspective.

conference objective

The objective of the Ninth National AIDS Update Conference is to provide a broad range of HIV and AIDS health care, education and service providers with the information needed to reshape existing systems in response to a changing epidemic.

conference objective includes emphasis on the following timely HIV-related issues:

- New research and recent advances in clinical management of persons with HIV infections;
- Effective prevention and education options;
- Early intervention, including counseling, testing and case management services;
- The emerging role of health care providers in the new era of HIV infection as a chronic disease;
- HIV-related ethical, legal, administrative, and policy issues;
- Issues related to specific populations affected;
- New questions of access and treatment financing, long-term care and housing for HIV-infected persons;
- Recently proposed legislative changes in health care;
- Alternative therapies.

conference focus

The conference program will include five tracks:

**Prevention and Education
Policy and Administration
Care and Services
Treatment and Health**

Adolescents and Young People

Each track will focus on conference objectives as they relate to the specific areas of interest. Cultural issues will be

integrated throughout each conference track. Dialogue between participants is strongly encouraged.

participant description

The program is especially relevant for physicians, nurses, and dentists; social service and mental health care workers; hospital service and planning managers; program administrators; local public health and government policy-makers. Individuals directly affected by HIV/AIDS are encouraged to attend.

conference sponsors

(partial list)

national/international

American Foundation for AIDS Research
American Hospital Association
American Medical Association
American Nurses Association
Association of Nurses in AIDS Care
Centers for Disease Control
Gay and Lesbian Medical Association
Health Initiatives for Youth
International Society for HIV/AIDS
Education and Prevention
Levi Strauss Foundation
National Association of Counties
National Association of People with AIDS
National Association of Social Workers
National Catholic AIDS Network
National Coalition of Hispanic Health & Human Services Organizations
National Hospice Organization
National Minority AIDS Council
The Hospital Research and Educational Trust
United States Conference of Mayors
United States Public Health Service/Health Resources & Services Administration

regional

AIDS and Chinese Medicine Institute
AIDS Health Project
California Academy of Family Physicians
California Association of Hospitals and Health Systems

California Department of Health Services.
Office of AIDS
California Nurses Association
Center for AIDS Policy Studies
Kaiser Family Foundation
Kaiser Permanente, Northern California Region
Los Angeles County Department of Health Services
Pacific AIDS Education and Training Center
San Francisco Department of Public Health
San Mateo County AIDS Program
University of California, San Francisco.
• School of Nursing, International Center for HIV/AIDS Research and Clinical Training in Nursing
• Center for AIDS Prevention Services
University of California, Universitywide AIDS Research Program
University of San Francisco, School of Nursing
Visiting Nurses and Hospice of Northern California

continuing education credit

Applications are pending for up to 19 hours of CME and CEU credit for physicians, nurses, social workers and health educators.

the mayor's summit

The Honorable Willie L. Brown, Jr., Mayor of the City and County of San Francisco, will convene the AIDS Summit in conjunction with the Ninth National AIDS Update Conference. The Summit, featuring the nation's leading experts on AIDS policy, is designed to keep San Francisco "ahead of the curve" in terms of delivery of AIDS care and services. Conference attendees are cordially invited to submit agenda items and to attend special sessions of the Mayor's Summit.

2 - 9th National AIDS Update Conference

program-in-brief

tuesday, march 18

noon- 8:00pm Registration
2:00pm- 5:00pm Intensive Workshops (additional fee)
5:30pm- 8:00pm Opening Reception
Exhibits Open

wednesday, march 19

7:00am- 6:00pm Registration
8:00am- 3:45pm Exhibits Open
8:00am- 9:00am Exhibit Viewing
Film Festival
Poster Viewing
9:00am- 9:15am Welcome
Special Achievement Award for Outstanding Leadership and Commitment to HIV/AIDS Awareness
9:15am-10:30am Plenary Session
10:30am-11:00am Coffee Break
11:00am-12:30pm Workshop I
12:30pm- 1:45pm Lunch and Roundtable Discussions
Theater Festival
Exhibit Viewing
Film Festival
Poster Viewing
1:45pm- 3:15pm Workshop II
3:15pm- 3:45pm Break
3:45pm- 5:15pm Workshop III
5:15pm- 6:00pm Theater Festival
Film Festival
Poster Viewing

thursday, march 20

8:00am- 5:00pm Registration
8:00am- 3:45pm Exhibits Open
8:00am- 9:00am Exhibit Viewing
Film Festival
Poster Viewing
9:00am-10:30am Plenary Session
10:30am-11:00am Coffee Break
11:00am-12:30pm Workshop IV
12:30pm- 1:45pm Lunch and Roundtable Discussions
Theater Festival
Exhibit Viewing
Film Festival
Poster Viewing
1:45pm- 3:15pm Workshop V
3:15pm- 3:45pm Break
3:45pm- 5:15pm Workshop VI
5:30pm- 6:30pm **Gala Conference Reception**

friday, march 21

8:00am- 5:00pm Registration
8:00am- 1:45pm Exhibits Open
8:00am- 9:00am Exhibit Viewing
Film Festival
Poster Viewing
9:00am-10:30am Plenary Session
10:30am-11:00am Coffee Break
11:00am-12:30pm Workshop VII
12:30pm- 1:45pm Lunch and Roundtable Discussions
Theater Festival
Exhibit Viewing
Film Festival
Poster Viewing
1:45pm- 3:15pm Workshop VIII

saturday, march 22

8:30am- 5:00pm HIV Over 50 Seminar (additional fee)

intensive workshops

tuesday, march 18 (2:00pm-5:00pm)

Advance Registration Required @ \$75 per Registrant

- 1. HIV Behind Bars: Providing Education, Advocacy, Care and Services**
An in-depth look at the complex issues that confront care providers and persons with HIV disease in prisons and jails. The session will cover policy, administrative, prevention and education, care and treatment issues. Women's issues will also be covered.
- 2. Developing Public Speaking and Presentation Skills for Trainers**
This session is designed for participants to work in a full group format and in smaller working groups to share techniques to solve actual problems or teach topics in an interactive method versus a lecture format.
- 3. HIV and the Immune System**
This session is designed for providers and other interested persons who want to increase their basic knowledge or who want to learn more about the immune system. This session will address the use of protease inhibitors.
- 4. Fund-Raising for HIV Organizations: Grant-Writing Tips and Techniques**
This session will present current and practical techniques for fund-raising and grant-writing. Participants will have an opportunity to discuss the issues and identify what their needs are.
- 5. Current Issues Affecting Adolescents and Young People**
The adolescents and young people track was one of the most popular at the 1996 conference. This session will update the trends and issues, and examine a variety of topics related to this population.
- 6. Social Work: Trends and Issues**
As the health care environment continues to change, so does the role of providers. Social workers have had to be creative as well as flexible during this challenging time. This session will deal with current trends and issues that affect the social work discipline.
- 7. Nursing Care and HIV: Present and Future**
The role of nursing and nurses is changing rapidly as the health care environment changes. This session will address current aspects of patient care, workplace, policy and resource issues.
- 8. Women, Children and Families**
Working with families dealing with HIV disease is one of the most challenging roles for the HIV provider. This session will address prevention, education, services, treatment and issues related to policy and funding for this rapidly increasing population.
- 9. Substance Abuse: Current Issues in the Changing Environment**
This popular session serves to update providers on current issues and trends that affect the client/patient as well as the provider. Harm reduction is an area that is covered as well as education, treatment and policy issues affecting this population.
- 10. Medical Treatment Update**
Much has changed since the last Update. This session will attempt to cover many of the trends and issues affecting the treatment of persons with HIV disease in the changing environment.

educational resource center exhibition and book fair

Educational materials, services and products from more than 100 organizations and companies will be on display throughout the Conference. The Resource Center and Exhibition is the traditional meeting place where conferees exchange the latest information and ideas about HIV/AIDS.

For the fourth year the Conference will feature an **HIV/AIDS Book Fair** presented by Green Apple Books. Over 2,000 book titles, videos and tapes will be on display for purchase. Author book signings will be scheduled throughout the Conference. To exhibit, contact: **KREBS Convention Management Services**

Phone: 415/255-1295 Fax: 415/255-2244

3 - 9th National AIDS Update Conference

events

AIDS in the arts

This art exhibit is a unique feature of the Update Conference. Artists living with AIDS, their caregivers and friends contribute to this beautiful and heart-felt collection. Artistic presentations include: hand-made quilts, woodblock prints, portraiture, interpretive oils, photography, sculpture, drawings and collages. For information, contact:

Katherine Krebs, CMP, Curator
Phone: 415/255-1295 Fax: 415/255-2244

AIDS theater festival

A theater festival dedicated to HIV/AIDS-related themes will take place daily. Plan to attend this popular feature. For more information, contact:

Hank Tavera, MEd, Festival Director
Phone: 415/554-8436 Fax: 415/554-9636

opening reception

Start networking early by attending the Opening Reception in the Exhibit Hall on Tuesday evening, March 18. Complimentary beverages and hors d'oeuvres will be served.

gala conference reception

All Conference attendees are welcome to attend a Gala Reception on Thursday evening, March 20. This event is one of many opportunities for networking and informal exchange with colleagues and friends. An important part of the learning experience occurs through interaction at this event.

roundtable talks

The popular Roundtable program held each day at 12:30pm is an opportunity to interact in small groups, discussing areas of mutual concern. Lunch will be available for purchase from on-site vendors.

film festival

Screenings of the latest HIV/AIDS-related films will be scheduled during the Conference. For information, contact:

Bea Tracy, Festival Director
Phone: 415/863-4826

time out and PWA lounge

A "Time Out Room" is set aside for all Conference participants to have a peaceful place to relax and share information gained from the presentations and workshops.

invited speakers

(partial list)

Hon. Willie L. Brown, Jr., Mayor, San Francisco, CA

Miguel Martinez-Bustos, Youth and AIDS Advisor, The White House, Washington, DC

Marcus Conant, MD, Conant Medical Group, San Francisco, CA

Lisa C. Capaldini, MD, Castro Medical Group, San Francisco, CA

Charles Garfield, PhD, Clinical Professor of Psychiatry, UCSF & Director, Charles Garfield Group, Oakland, CA

Sandra Hernandez, MD, Director, San Francisco Department of Public Health

Mervyn F. Silverman, MD, MPH, President, AmFAR, New York, NY

Bruce Czuchna, PsyD, Cook County Hospital, Chicago, IL

Jeff Getty, AIDS Activist, Oakland, CA

James W. Dilley, MD, Director, AIDS Health Project, University of California, San Francisco

Ron Stall, PhD, MPH, Associate Professor, Center of AIDS Prevention Studies, UCSF

Martin Ornelas-Quintero, Executive Director, National LLEGO, Washington, DC

Gary Stein, JD, Project Director, HIV Professional Development Project, New York Academy of Medicine, New York, NY

Russ Toth, MEd, MBA, MPH, Director, California AIDS Clearinghouse, Los Angeles, CA

Ellen Parish, RN, MPH, New York Academy of Medicine, New York, NY

Tooru Nemoto, PhD, Institute for Health Policy Studies, UCSF

Pat Norman, Executive Director, Institute for Community Health Outreach, San Francisco, CA

Nathan Linsk, PhD, Midwest AIDS Training & Education Center, Chicago, IL

Fr. Rodney DeMartini, SM, Executive Director, National Catholic AIDS Network, San Francisco, CA

Inge Corless, RN, PhD, FAAN, Massachusetts General Hospital, Institute of Health Professions, Boston, MA

Owen Borda, Executive Director, Westchester Co. AIDS Council, New York, NY

Scott Cozza, LCSW, ACSW, Prison Advocate, Petaluma, CA

conference organization

conference co-chairs

Mary Pittman, DrPH
President, The Hospital Research & Educational Trust
The American Hospital Association
Chicago, IL

Paul Kawata
Executive Director, National Minority AIDS Council, Washington, DC

conference program director

Cliff Morrison, MS, MN, RN, FAAN
Assistant Dean, School of Nursing
University of San Francisco
San Francisco, CA

conference track chairs

Prevention and Education

Helen Miramontes, MS, RN, FAAN
Associate Clinical Professor & Deputy Director, The International Center for HIV/AIDS Research & Clinical Training in Nursing, University of California
San Francisco, CA

Ron Stall, PhD, MPH
Associate Professor, Center for AIDS Prevention Studies, University of California, San Francisco, CA

Policy and Administration

Helen Scheitinger, MA, RN
AIDS Policy Consultant, Washington, DC

Mervyn F. Silverman, MD, MPH
President, AmFAR, New York, NY

Care and Services

Ana Garcia, LCSW, Pediatric AIDS Program, Division of Pediatric

Immunology & Infectious Disease
University of Miami, Miami, FL

Jeremy Landau
Non-Profit Management Consultant
Member, Presidential Advisory Council on AIDS, Santa Fe, NM

Treatment and Health

Joseph O'Neill, MD, MPH
Director, AIDS Program Office
HRSA, Rockville, MD

Anita Vaughn, MD
Medical Director, Newark Community Health Centers, Newark, NJ

Adolescents and Young People

Janet Shalwitz, MD
Executive Director, Health Initiatives for Youth, San Francisco, CA

Ron Henderson
Health Initiatives for Youth
San Francisco, CA

4 - 9th National AIDS Update Conference

workshops

To help plan meeting space, select eight workshops in which you have the most interest. You are not bound by this preliminary selection. Program and speakers are subject to change.

Prevention and Education

- 101 Community Issues in HIV Prevention
- 102 Prevention Issues for the Incarcerated Population
- 103 HIV Prevention and People with Mental Illness
- 104 HIV and STDs: What Are the Issues?
- 105 Long-Term Effects of Childhood Sexual Abuse: The Connections to High Risk Behaviors
- 106 Prevention Efforts for Indigenous People
- 107 National Latino/a Lesbian & Gay Organization (LLEGO) Prevention Strategies
- 108 Psychosocial Correlates of Unprotected Sex in HIV Negative Gay Men
- 109 HIV Prevention in the African-American Community
- 110 Surviving with HIV/AIDS: Long-Term Survivors
- 111 Outreach Strategies among Asians and Pacific Islanders
- 112 Prevention Efforts in Rural Communities
- 113 Prevention and Education for Older Persons
- 114 Women and Prevention Issues
- 115 Gay Men and HIV Prevention
- 116 Lesbians and HIV: The Magnetic Couples Institute
- 117 Minority Community Outreach: California Health Outreach Training
- 118 The Need for Transgendered Peer Educators

Policy and Administration

- 201 Ryan White: Service Standards, Evaluations and Peer Review
- 202 HIV+Workers: Challenges and Issues
- 203 Managed Care and Case Management: What Are the Issues Now?
- 204 Fund-Raising and Other Administrative Challenges
- 205 Long-Term Care and Housing: Developing a Needs Assessment
- 206 Policy Issues in Small Towns and Rural Areas
- 207 Counseling and Support Groups: Issues and Challenges
- 208 Emerging Policy Issues for Correctional Institutions
- 209 Substance Abusers: Expectations of Providers
- 210 Pregnant Women and Newborns: The New Focus of Mandatory Testing Efforts
- 211 Recruiting African-American Church Leaders as AIDS Advocates
- 212 Puerto Rico: AIDS and Its Impact among the Unmentioned Territory
- 213 Advance Practice Nursing: Do We Need Specialization in HIV/AIDS?
- 214 HIV Over 50: Organizing Networks and Programs
- 215 Planning Services for Persons with HIV/AIDS: What's New?
- 216 The Response to Transfusion Associated HIV/AIDS

Care and Services

- 301 Clinical Trials and Research Studies: Has Anything Changed?
- 302 Case Management: Issues, Resources and Solutions
- 303 Housing Issues Today: Have the Needs Changed?
- 304 Addiction Services in HIV/AIDS Care
- 305 Spiritual and Religious Issues for Persons Living with HIV Disease
- 306 Hospice and Home Care Issues in a Changing Environment
- 307 Care Issues for the Incarcerated: Resources and Access
- 308 Complementary and Alternative Care Issues: How Do They Fit in Today's Changing Environment?
- 309 Care and Services for Children and Families
- 310 Care and Services for Hispanics and Latinas/os
- 311 Dealing with the GI Complications of HIV
- 312 Caregiving: What Caregivers Need

- 313 Health Insurance and Disability Benefits: What Are the Trends?
- 314 Ethical Dilemmas and Changing Issues in HIV Care
- 315 Care and Services for Women: Advocacy, Access and Resources
- 316 Prophylaxis: A Review and Update
- 317 Integrating Mental Health Services for Persons with HIV Disease

Treatment and Health

- 401 HIV/AIDS Experiences of Primary Care Physicians: A National Survey
- 402 Pulmonary Disease in HIV
- 403 Ophthalmologic Disease and HIV
- 404 Pediatric HIV/AIDS: Care and Treatment
- 405 Women, Children and HIV Disease
- 406 Care and Treatment in Prisons and Jails
- 407 Primary Care Approach to Psychiatric Complications
- 408 Chinese Medicine and HIV Care and Treatment
- 409 Neoplastic Complications of HIV Disease
- 410 Dermatological Disease in HIV and AIDS
- 411 Neurological Complications and HIV Disease
- 412 Dental and Oral Health
- 413 Gastrointestinal Disease in HIV
- 414 Protease Inhibitors: Understanding Their Use

Adolescents and Young People

- 501 HIV and Young Women
- 502 Youth Substance Use and HIV Risk
- 503 Prevention for Young Gay and Bisexual Men
- 504 Cutting Edge Prevention Strategies
- 505 HIV and Homeless Youth
- 506 Primary Care for HIV Positive Youth
- 507 Childhood Sexual Abuse and Adolescent HIV Risk
- 508 Legal and Ethical Issues in HIV Testing of Youth
- 509 HIV and African-American Youth
- 510 HIV and Latino Youth
- 511 HIV and Asian/Pacific Islander Youth
- 512 HIV and Native American Youth
- 513 Advanced Counseling for HIV Risk Behavior Change
- 514 Peer Education and Support Programs
- 515 Dual- and Triple-Diagnosed Youth
- 516 Activism and Advocacy for HIV Positive Youth

HIV over 50 seminar

saturday, march 22 (8:30am-5:00pm)

Advance Registration Required @ \$75 per Registrant

This seminar discusses issues of aging and AIDS and examines several types of networks and organizations that have begun to emerge. Implications for support, service and prevention will be considered and resource materials provided. For information, contact:

NAHOF (National Association on HIV Over Fifty)
Co-Chair Jane P. Fowler, Good Samaritan Project
3030 Walnut Street
Kansas City, MO 64108
Phone: 816/561-8784 Fax: 816/531-7199

poster session

Poster sessions, featuring author discourse, will be displayed during the Conference. Posters will be categorized according to the five Conference tracks: **Treatment and Health, Policy and Administration, Prevention and Education, Care and Services, and Adolescents and Young People.** For information, contact:

Seiff Morrison, Conference Program Director
Phone: 415/206-1644 Fax: 415/206-0796

TALK OF THE NATION: SCIENCE FRIDAY

WNYC RADIO ONE CENTRE STREET NEW YORK, NY 10007 (212) 669-2297/8561

TO: Patricia Fleming (202) 632-1046 FAX

FROM:

☒ Karin Vergoth 212-669-8561☐ Amy Sirot 212-669-3308☒ 2 Pages, including cover sheet

Science Friday Fax # - 212-669-8642

Thanks again for being on the
program. Please sign this release
form and FAX it back to me
at the number above.

Thank you,
Pam

CP - Please handle

Faxed 1/24/97 P

NATIONAL PUBLIC RADIO®



SCIENCE FRIDAY
RELEASE FORM

1. I, the undersigned individual, agree to participate in the program "Science Friday", produced by Samana Productions, and distributed as part of National Public Radio's "Talk of the Nation" series. I agree that the Program will be recorded and distributed in various media including, but not limited to, public and commercial broadcasting, compact disc, audio cassette, on-line, electronic and all other forms of distribution and reproduction now or hereafter known, worldwide (hereafter the "Project").
2. My participation is through interview, commentary, discussion, performance and/or the like, (hereinafter collectively referred to as the "Work"), and shall be governed by this Release
3. In consideration of the inclusion of my Work in the Project, and for other good and valuable consideration, I irrevocably grant to Samana Productions and NPR each, exclusive, assignable licenses to reproduce, distribute, publish, display, disseminate, perform, exhibit, compile and otherwise exploit all Work provided by me, in whole or in part, in any manner or medium, now or hereafter known, for all commercial and noncommercial uses worldwide, in perpetuity
4. I acknowledge that I can grant the rights set forth in this Agreement, that I have the authority to enter into and perform this Agreement, and that I am under no contract with any person or entity which will interfere with my performance of this Agreement nor will I enter into one
5. This release shall be governed by the laws of the District of Columbia (without reference to its conflict of law rules) and the laws of the United States whether or not the Work is performed within or without these jurisdictions.

Date this _____ day of _____, 199__

Printed Name _____

Patricia S. Fleming
Signature _____

Address _____

Telephone _____

SS# _____

**Proposed agenda with AIDS Policy Advisory Patricia Fleming
Tuesday, January 28, 1997, 10:30 a.m.**

- I. To confirm that our missions are substantially alike;
 - A. Sabin Foundation advocates vaccines, *including an AIDS vaccine*
 - B. You seek total victory against AIDS, *including an AIDS vaccine*
- II. To propose that, even with scientific success, an AIDS vaccine requires:
 - A. Advance analysis of social consequences, issues such as identified in initial studies performed for Sabin Foundation by Dr. Martin Levin of Brandeis, et. al.
 - B. Citizen education of the need for immunization to achieve eradication of AIDS
 - C. A credible and orderly plan for distribution that is not afflicted by the suspicions and misinformation now associated with vaccines
 - D. Leadership such as Basil O'Connor exercised in transforming the fight against Infantile Paralysis into the March of Dimes
 - E. Investment that will accelerate eradication of AIDS by providing the vaccine to those of high risk but low means
- III. To ask your endorsement and support in convening selected leaders of the vaccine industry, vaccine science, health policy, insurance, finance, medical journalism and public affairs, for the purpose of:
 - A. forming a public/private leadership consortium, and
 - B. drafting a national citizen action plan that will compliment efforts toward scientific solutions.



THE SECRETARY OF HEALTH AND HUMAN SERVICES
WASHINGTON, D.C. 20201

JCS
on calendar 1/21/87
Q

The Secretary of Health and Human Services

cordially invites you to

a farewell reception for

Philip R. Lee, M.D.

Assistant Secretary for Health

on Wednesday, January twenty-ninth
from three until five o'clock


Suite 615-F

Hubert H. Humphrey Building
200 Independence Avenue, S.W.

Regrets only

202/690-6174

yes
accepted 1/21/97
v m c
or Gabe's



Bid a fond farewell to

Phil Lee

January 28, 1997 at 6:30pm
Afghan Kabob Restaurant
3320 M St., NW
(Georgetown)

Buffet Dinner
Cash Bar

\$37.50-- includes appetizers, dinner, tax & gratuity.

RSVP by Jan. 22 to Eileen Conover, 690-7694
Please make payment by Friday, Jan. 24 to
Hal Thompson, Room 709H, 205-0677 or
Damon Thompson, Room 725H, 205-1842

Contributions for a gift will also be accepted.

URGENT
FALL

RUSH TO: Jeff Levi, White House Office of AIDS Policy

FAX: 202 6321096

FROM: David Barr- Gay Men's Health Crisis

PAGES (INCLUDING THIS COVER): 2

Thursday, January 9, 1997

To: Members of the Forum for Collaborative HIV Research

From: Interim Executive Committee

Date: January 9, 1997

Re: Upcoming meeting

We have planned a meeting of the full membership of the Forum for Sunday, January 26th from 1:00 to 5:00 pm at the Renaissance Mayflower Hotel, 1127 Connecticut Avenue, NW in the Senate Room. Lunch will be available starting at 12:00.

This meeting was planned at this time because a large number of Forum members will already be in Washington for the Retrovirus Conference. The Conference ends Sunday morning, giving people time to come down to the Mayflower for a Forum meeting. The meeting will give the Executive Committee an opportunity to brief the membership on the status of things and for all us to discuss the next steps. A tremendous amount of work has been accomplished since September.

Please RSVP by calling David Barr at 212-337-1904.

We look forward to seeing you on January 26th.

yes

Left message on voice mail 1/10/97
on calendar



THE SECRETARY OF HEALTH AND HUMAN SERVICES
WASHINGTON, D. C. 20201

*Please join me at a reception
and buffet dinner
to bid farewell to*

*Shirley Chater
Commissioner of Social Security*

*in my office
on Thursday, January 23
at 6:30 o'clock*

*R.S.V.P.
202/690-6174*

Patsy — You should have
rec'd. this in mail.
David

yes
on calendar
1/21/97



THE SECRETARY OF HEALTH AND HUMAN SERVICES
WASHINGTON, D.C. 20201

Please join me at a reception
and buffet dinner
to bid farewell to

Shirley Chaler
Commissioner of Social Security

in my office
on Thursday, January 23
at 6:30 o'clock

R.S.V.P.

202/690-6174

THE WHITE HOUSE
WASHINGTON

JAN 14 1997

BY FAX: 703-299-0204

MEMORANDUM TO RETROVIRUS CONFERENCE STEERING COMMITTEE

FROM: Patricia S. Fleming 
Director
Office of National AIDS Policy

SUBJECT Request to attend the Conference opening January 22, 1997

ATTN: Melissa A. Sordyl

I am requesting permission to attend the opening session of the Retrovirus Conference on January 22.

In my capacity as Director it would be beneficial to be able to attend the opening session on Wednesday, January 22.

Your cooperation in this matter would be greatly appreciated.

W. H. Lindner
Senior Advisor to Conference Chairman

12th World AIDS Conference
28 June - 3 July, 1998 Geneva

Executive Secretary
Geneva Secretariat
Temporary Address
Geneva University Hospital
Division of Infectious Diseases
1211 Geneva 14 Switzerland

Tel: 41 22 372 9806

E-Mail : Lindner@dminov1 hcuge.ch

Fax : 41 22 372 9820

CP Schedule
+ return

on calendar
22-26 Jan
11/02
A

TO: Ms Patricia Fleming

FROM: W. H. Lindner

DATE: 12 November, 1996

No. of Pages: 6 (including cover)

Dear Ms Fleming,

I know that recently Richard Burzynski met with you in Washington and mentioned my role in the upcoming 12th World AIDS Conference.

I plan to be in Washington during the 4th Retrovirus conference and would very much enjoy meeting you, if you were to be in Washington and available at that time.

I gather from Richard that he gave you half of my cv since that was all he received from the organizers, so I have enclosed a complete version for your perusal. As indicated in the CV one of my principal areas of responsibility for '98 is the North/South dimensions of the pandemic and the accessibility issue. Since my background has been in 'sustainable development', the economic and other disparities between the industrialised countries and the lesser developed ones are of primary concern to me. Indeed, many of the same analytic processes must be used in dealing with the spread of HIV as are used in the moving towards sustainable development, e.g., 'getting at the root causes' and not dealing only with the effects.

In any event, hope you will be in Washington and look forward to hearing from you. I, of course, will take background material on the '98 conference with me to Washington, but if you would like any additional information in the meantime, please do let me know.

CC: Richard Burzynski w/o encls.

Withdrawal/Redaction Marker

Clinton Library

DOCUMENT NO. AND TYPE	SUBJECT/TITLE	DATE	RESTRICTION
001. resume	[Personally Identifiable Information] [partial] (1 page)	11/11/1996	b(6)

COLLECTION:

Clinton Presidential Records
National AIDS Policy Office
Patsy Fleming (National AIDS Strategy)
OA/Box Number: 10181

FOLDER TITLE:

[Invitations 1996-1997] [3]

2018-0755-F

rs3181

RESTRICTION CODES

Presidential Records Act - [44 U.S.C. 2204(a)]

P1 National Security Classified Information [(a)(1) of the PRA]
P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
P3 Release would violate a Federal statute [(a)(3) of the PRA]
P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

Freedom of Information Act - [5 U.S.C. 552(b)]

b(1) National security classified information [(b)(1) of the FOIA]
b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

PERSONAL RESUME

11 November, 1996

Name: : Warren H. Lindner

Current Position : Senior Advisor to Chairman
Executive Secretary
12th World AIDS Conference

Home Address : 34 rue Jean-Violette
Appt. 42
1205 Geneva, Switzerland

Telephone : Office: 4122 372 9806
Home: 4122 320 49 44

Fax : Office: 4122 372 9820

E-Mail: 101376.3300@CompuServe.Com

Personal Data : Citizen of the U.S.A., born (b)(6)
Age 54,; divorced with four children, ages 25, 23, 19,
and 17; Height: 5'10"; Weight: 170 lbs.

PROFESSIONAL EXPERIENCE

June 1996 to present:

Senior Advisor to Chairman and Executive Director of the 12th World AIDS Conference to be held in Geneva, Switzerland June 28 - July 3, 1998 with principal responsibilities being (i) to ensure a visible focus on the North/South dimensions of the HIV/AIDS pandemic, particularly as regards access to treatment, drugs and care; and (ii) to assist in the overall management of the planning process for the '98 conference.

April 1988 to December, 1995

Executive Director, the Centre for our Common Future, a Swiss charitable foundation, founded in April 1988 to mark the first anniversary of the issuance of the report of the World Commission on Environment and Development (the 'Brundtland Commission'), 'Our Common Future'.

Since its inception its principle missions have been (i) to act as a non-partisan information exchange mechanism and a global information clearinghouse on sustainable development initiatives, (ii) to further public participation in the search for sustainability, (iii) to foster inter-sectoral dialogue on key issues related to sustainability and (iv) to build and service networks of groups from different sectors of society and different regions of the world for the creation of new working partnerships for sustainable development.

Over the past eight years, the Centre has been instrumental in preparing and packaging key information on sustainable development and servicing thousands of organisations and institutions around the world which have committed themselves to furthering the principle of sustainable development. It now has more than 265 'Working Partner' organisations and institutions in more

than 70 countries that work with it and a database of more than 85,000 organisations and institutions working on sustainable development in over 200 countries. These organisations represent all sectors of society, including environment and development groups; women's organisations; government agencies and ministries; international organisations; indigenous peoples; youth groups; the scientific and academic community; trade unions; business and commerce; the legal profession; and the media.

During the period since its creation, the Centre, under the leadership of the Executive Director, has, among other things:

- provided advice and materials on sustainable development to more than 500 conferences and symposiums throughout the world,
- arranged the publication of *Our Common Future* in 23 languages,
- researched and published a follow-up report to *Our Common Future* entitled 'Signs of Hope',
- produced a five-hour live television broadcast on the theme of sustainable development which involved the participation of 17 heads of government and numerous 'rock' celebrities (this programme was shown in 52 countries throughout the world),
- organised 11 ECO '92 Public Forums around the world in preparation for the Earth Summit held in Rio de Janeiro in June, 1992 (these forums involved the participation of over 10,000 organisations),
- organized Global Forum '92, held in Rio de Janeiro in connection with the Earth Summit (this event had over 28,000 registered participants from more than 18,000 organisations, 9,000 press and more than 425,000 visitors during its fourteen days)
- published more than forty editions of 'The Network' (the Centre's monthly newsletter which reports on the Rio Earth Summit and its follow-up) which is produced in five languages and has a worldwide circulation of over 45,000 organisations, as well as 23 issues of 'The Bulletin' (the Centre's quarterly journal which tracks sectoral initiatives to achieve sustainable development),
- written and published, in cooperation with the Swiss government, 'Agenda for Change: A Plain Language Version of Agenda 21' which has now been translated and produced in nine languages (with seventeen additional languages in preparation) and has reached a world-wide distribution of over 300,000 copies.

The Centre recently launched a training programme on the post-Rio multilateral processes for young professionals from developing countries and is currently working to expand its database so as to be able to provide a service to developing country institutions on financing and training opportunities, both in the North and in the South.

August 1984 to March 1988

Secretary, World Commission on Environment and Development, an independent body created under the auspices of the United Nations to conduct a three year world-wide enquiry into the relationship between environment and economic development.

The Commission was headed by the Prime Minister of Norway, Mrs. Gro Harlem Brundtland and had as members 21 senior political and scientific leaders from around the globe, including among others, Sir Shridath Ramphal, Secretary General of the Commonwealth of Nations, William Ruckelshaus, former Administrator of the U.S. Environmental Protection Agency, Dr. Saburo

Okita, former Foreign Minister of Japan, Susanna Agnelli, current Foreign Minister of Italy; and Dr. Mansour Khalid, former Foreign Minister of Sudan.

The Commission's mandate was to re-examine the critical issues of environment and development and to formulate innovative, concrete and realistic action proposal for governments, institutions and peoples to deal with them and to raise global awareness on the issues. Its final report, 'Our Common Future' [which, through the Centre has been published in 27 languages] was the outcome of three years of fact-finding and consultation conducted in public in all the regions of the world, with the aid of governments, institutions and citizens groups.

As Secretary of the Commission, was responsible for the management and operational aspects of the Commission's activities world-wide, including: its official meetings and visits to 16 countries; the public hearings it held in 10 countries; and the presentation of its final report 'Our Common Future' to heads of governments and ministers from over 100 countries.

Was also responsible for the daily management and direction of the Commission's secretariat in Geneva [15 senior professional staff and 10 support staff from 14 countries], for overseeing its press and public information programme and for the financial management of the Commission, including the establishment and control of its budget [approximately \$8 million] as well as for all fundraising efforts for the Commission.

August 1982 - August 1984

Director of the Energy Department with Société Générale pour l'Energie et les Ressources [Sogener] a publicly quoted Swiss energy and merger/acquisition company located in Geneva, Switzerland, which until 1982 was a 42% owned subsidiary of Tosco Corporation. During this period, worked closely with, and primarily for, the company's principal shareholder, Maurice F. Strong [former Chairman of the Board of Petro-Canada, Chairman of the Board of Canada Development Investment Corporation, principal shareholder of Tosco Corporation, former Secretary General of the Stockholm Conference in 1972, Under-Secretary General of the United Nations, and Secretary General of the Rio Earth Summit].

In this capacity represented and acted on behalf of Mr. Strong in the conduct of his international business activities including the disposition of his controlling interest in a publicly traded Swiss holding company, Credit Immobilier, to Tosco Corporation and the reacquisition of that company from Tosco by a group of international investors and its on-sale to a Geneva investment group.

Also acted on behalf of Sogener, Credit Immobilier and their principal shareholders in the acquisition and disposition of various investment interest and when needed provided general legal advice in respect of their activities particularly in the U.S. Also served as a consultant to Sogener's merger/acquisition subsidiary Interfinexa S.A.

November 1980 - August 1982

Deputy Director General of the WorldWide Fund for Nature (formerly the World Wildlife Fund), an international charitable conservation foundation based in Gland, Switzerland [with 26 affiliate organizations on five continents] whose main objective is the raising of funds for allocation to conservation and development projects around the world.

During this period, served as Deputy Director General at WWF's International Headquarters, with primary responsibility for the administration of the International Secretariat, and representation of the Director General and the institution at high level meetings.

Was also responsible for the management of divisional directors' activities and the activities of and relations with, the foundation's Board of Trustees, which included, among others, his Royal Highness the Duke of Edinburgh, Dr. Anton Rupert, Chairman of the Rupert Group of Companies, Mr. John Loudin, former Chairman of the Board of the Royal Dutch Petroleum Company, Mr. David Ogilvy, founder of Ogilvy & Mather, Sir Arthur Norman, Chairman of the Confederation of British Industry, Mr. Joseph Cullman, Chairman of the Executive Committee of Philip Morris and Sir Peter Scott.

Also worked closely with WWF's 26 national affiliates in the development and implementation of international policy and the development of international and national fund-raising opportunities.

October 1972 - November 1980

Senior Associate and (from 1977) partner of United States law firm, Vinson & Elkins. During this period, represented and advised the firm's clients in the conduct of their corporate and financial operations in the United States, the U.K., Europe and Africa.

As senior attorney had specific and primary responsibility for, among others, the following projects:

1. The natural resources division of Amex Bank Limited (formerly Rothschild Intercontinental Bank) in the negotiation and drafting of a US\$ 27 million petroleum project financing in Zaire;
2. Champlin Petroleum Company in the negotiation of the sale of all of its North Sea petroleum interests;
3. First Arabian Corporation, a Saudi Arabian holding company, for the acquisition and management of its U.K. investments; and
4. Occidental Petroleum Corporation in the negotiation of US\$ 780 million of project development financing for its North Sea operations.

September 1971 - August 1972

Member of the staff of Marymount International School, Neuilly-sur-Seine, France. Taught junior high school courses in English, History and Current Affairs.

February 1969 - September 1971

Associate Attorney with U.S. law firm, Mayer, Brown & Platt, Chicago, Illinois. During this period worked principally with the natural resource financing division of the Continental Illinois National Bank & Trust Company of Chicago. In this capacity, handled negotiations and drafting of loan agreements, security documents, pledges and collateral agreements, particularly for natural resource financing arranged through the Continental Bank, including a US\$ 500 million financing for American Metal Climax.

During this period, spent ten months in France, providing service in the Paris office of the firm, acquiring knowledge of French law, and developing skill in French language.

At end of assignment in Paris, traveled for an extended period on a worldwide basis throughout Europe, Africa, the Middle East and Asia.

EDUCATION AND LANGUAGES

Juris Doctorate degree (1969) from Duke University Law School, Durham, North Carolina. Curriculum included International Studies; graduated in top 10% of class. Admitted to the Bar of the State of Illinois.

BA degree (1965) in Psychology, minor in International Relations, from the University of Denver, Denver, Colorado. During university was active in numerous student activities, including, among others, Vice-President of the Freshman Class; President of the Sophomore Class; two terms as President of the Student Body; local President and National Vice-President of Inter-Collegiate Knights (National honorary and service organisation); delegate to White House National Student Leadership Conference; member of Omicron Delta Kappa, national academic and service organisation; member of Lambda Chi Alpha fraternity; and only student in University's history to receive its highest leadership award, 'The Chancellor's Special Award for Leadership'.

College preparation at Mount St. Joseph Preparatory School, Baltimore, Maryland.

Languages: Fluent French

ASSOCIATIONS:

Previously,: member of the International Advisory Board of Globe '90 and Globe '92; member of the International Advisory Board of Earth Day, 1990 and 1991; Vice-President of Gulf International Corporation; Member of the Board of Trustees of the North South Roundtable and Gaia Foundation; Treasurer of the North South Roundtable.

Currently member of: the Editorial Board of Tomorrow Magazine; the Advisory Board of Gallup International; the Policy Advisory Board of the Earth Council; the World Commission on Financing the United Nations; The Gensis Facility; and a member of the Board of the Panos Institute.

REFERENCES

Gro Harlem Brundtland,
Former Prime Minister of Norway

Maurice Strong,
Senior Advisor, World Bank,
former Under-Secretary
General, United Nations

Klaus Schwab,
President, World Economic Forum

Gus Speth,
Executive Director, United
Nations Development Program

Emil Salim,
Chairman, World Commission on Forestry
Former Minister of Population, Indonesia

Mansour Khalid, President,
African Centre for Environment,
former Minister of Foreign Affairs, Sudan

*Laszlo & Associates, Inc.
Cordially invites you to join elected
officials and activists for an
inaugural brunch honoring*

*Donald Fowler
Chairman,
Democratic National Committee*

*Lisbeth C. Evans
Chairwoman,
North Carolina Democratic Party*

*Stop by for food and conversation
at 1823 Jefferson Place, NW
Washington DC
Saturday, January 18th
11 am - 1 pm
R.S.V.P 202-955-0060*

EXECUTIVE OFFICE OF THE PRESIDENT

11-Dec-1996 10:47am

TO: FLEMING_P
TO: FLEMING_P
FROM: Toby Donenfeld

*on calendar
12/11*

SUBJECT: Re: Harvey meeting

Message Creation Date was at 11-DEC-1996 10:47:00

We're set to meet with David Harvey from the AIDS Policy Center on Wednesday January 8 at 3pm in Greg's office.

E X E C U T I V E O F F I C E O F T H E P R E S I D E N T

11-Dec-1996 11:05am

TO: Carmena Parris

FROM: Patsy Fleming
 AIDS Policy Council

SUBJECT: Please schedule

Laszlo & Associates, Inc.

To: Patricia Fleming

Attn: Carmena Parris

From: Jennifer Laszlo

Date: January 9, 1997

As part of the Inaugural weekend, I am writing to invite you to a special brunch in recognition of the enormous dedication and work of party leaders. The brunch is meant as a "thank you" to many who have toiled diligently on behalf of the Democratic party. Specifically, we will be honoring Don Fowler, Chairman of the Democratic National Committee, and Libba Evans, chair of the North Carolina Democratic Party -- my home state. We are inviting all state chairs and their families to attend, as well other national leaders such as yourself. I would be delighted if you would come by, and I know that it would mean a lot to our honorees.

In order to be convenient to the many people coming in from out of town, the brunch will be held at my downtown office on Saturday, January 18th, from 11:00-1:00. Other than a few comments from our honorees, there will be no formal program -- only a wonderful opportunity to see friends new and old.

Following is an invitation to the brunch which includes directions. Please feel free to bring a guest. RSVP's are being taken by Michelle Feinstein in my office at 202-955-0060.

I look forward to seeing you at the party!

*No thanks.
declined w/ Heather 1/10/97*

Laszlo & Associates, Inc.

*Cordially invites you to join elected officials and
activists for an inaugural brunch honoring*

Donald Fowler

Chairman, Democratic National Committee

Lisbeth C. Evans

Chairwoman, North Carolina Democratic Party

for

Their hard work, vision & dedication to our country

Stop by for food and conversation

at 1823 Jefferson Place, NW

Washington DC

Saturday, January 18th


11 am - 1 pm



**RSVP to
(202) 955-0060**

Directions:

Laszlo & Associates Inc. is
located between Connecticut
Ave. and 19th Street, N.W. and
M and N Streets.



Laszlo & Associates, Inc.

*Cordially invites you to join elected officials and
activists for an inaugural brunch honoring*

Donald Fowler

Chairman, Democratic National Committee

Lisbeth C. Evans

Chairwoman, North Carolina Democratic Party

for

Their hard work, vision & dedication to our country


Stop by for food and conversation

at 1823 Jefferson Place, NW

Washington DC

Saturday, January 18th


11 am - 1 pm



**RSVP to
(202) 955-0060**

Directions:

Laszlo & Associates Inc. is
located between Connecticut
Ave. and 19th Street, N.W. and
M and N Streets.



01/09/97

14:45

11 301 402 1505

DIVISION OF AIDS

001

Did not attend

DIVISION OF AIDS

NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

NATIONAL INSTITUTES OF HEALTH

Office of the Director
6003 Executive Blvd.
Bethesda, Maryland 20892-7620
Phone: 301-496-0545
FAX: 301-402-1505

FACSIMILE TRANSMISSION

DATE: January 9, 1997

TO: *Patsy Fleming*

FAX #: *202-632-1096*

COMMENTS:

See attached information for January 14, 1997 meeting

*CP-
I'm going to this
next week.
I've scheduled
hold for 1/14*

*Would you
call re
parking?*

*✓ Visit
NIH Lots of B&C P*

NUMBER OF PAGES: 5 (including this transmission sheet)

FROM:

Jack Killen, M.D.

STUDIES OF TRANSPLACENTAL CARCINOGENESIS OF AZT

DRAFT AGENDA

January 14, 1997

- | | | |
|-------|--|-----------------------------|
| 9:00 | Introductions, opening remarks
Goals for this meeting | Dr. Killen
Dr. Killen |
| 9:10 | Background <ul style="list-style-type: none">• Use of AZT in prevention of perinatal transmission• Transplacental carcinogenesis: the mouse model | Dr. Smiley
Dr. Anderson |
| 9:30 | NCI study | Dr. Poirier
Dr. Anderson |
| 10:30 | Glaxo-Wellcome study | Dr. Ayers
Dr. Smiley |
| 11:30 | Other relevant data and information <ul style="list-style-type: none">• ACTG 219 and other long-term follow-up studies• Ongoing and planned clinical trials | Dr. McNamara |
| 12:00 | LUNCH | |
| 1:00 | Discussion by panel <ul style="list-style-type: none">• Interpretation of currently available information• Future research directions | Panel |
| 2:00 | Informing the community <ul style="list-style-type: none">• The content• The methods | Panel |
| 3:00 | Opportunity for open discussion, questions, comments | |
| 3:30 | Summary | Dr. Killen
Panel |
| 4:00 | Adjourn | |

Studies of Transplacental Carcinogenesis of AZT

January 14, 1997

Natcher Conference Center
Conference Rooms E1/E2

Chair

John Y. Killen, M.D.
Director
Division of AIDS
National Institute of Allergy
and Infectious Diseases
Solar Building, Room 2A-20
6003 Executive Boulevard
Bethesda, Maryland 20892
(301) 496-0545

Panel Members

Arthur J. Ammann, M.D.
Pediatric AIDS Foundation
81 Digital Drive
Novato, California 94949
(415) 883-5621

Ronald Bayer, Ph.D.
Columbia School of Public Health
600 West 168th Street
New York, New York 10032
(212) 305-1957

William A. Blattner, M.D.
Institute of Human Virology
University of Maryland
725 West Lombard Street
4th Floor
Baltimore, Maryland 21201
(410) 706-1941

Edward Bresnick, Ph.D.
Office of Research
University of Massachusetts
Medical Center
55 Lake Avenue North
Worcester, Massachusetts 01655
(508) 856-1638

Jacqueline Clements
4008 Tyne Drive
Durham, North Carolina 27703
(919) 596-6171

Howard Minkoff, M.D.
SUNY/Brooklyn
Health Science Center at Brooklyn
445 Clarkson Avenue
Brooklyn, New York 11203
(718) 270-2860

Eileen Monaghan
5170 Route 31
Spencerport, New York 14559
(716) 352-5202

Nancy E. Mueller, S.D.
Harvard School of Public Health
677 Huntington Avenue
Boston, Massachusetts 02115
(617) 432-1050

June Osborn, M.D.
Macy Foundation
44 East 64th Street
New York, New York 10021
(212) 486-2424

Henry Pitot, Ph.D.
McArdle Laboratories
University of Wisconsin
1400 University Avenue
Madison, Wisconsin 53706-1599
(608) 262-3247

Jean-Pierre Sommadossi, Ph.D.
University of Alabama at Birmingham
Department of Pharmacology
University Station
VH-600
Birmingham, Alabama 35294
(205) 934-8226

Patricia N. Whitley-Williams, M.D.
University of Medicine and Dentistry
of New Jersey
Robert Wood Johnson Medical School
1 Robert Wood Johnson Place - CN19
New Brunswick, New Jersey 08903-0019
(908) 235-7894

Gerald Wogan, Ph.D.
Massachusetts Institute of Technology
Division of Toxicology
77 Massachusetts Avenue
Room 16-333
Cambridge, Massachusetts 02139
(617) 253-3188

ADVISORY: Upcoming Scientific Meeting On Recent Studies in Mice to Evaluate Transplacental Toxicity of AZT

When: Tuesday, January 14, 1997, 9 a.m. to 4 p.m.

Where: Conference Rooms E1/E2 of the Natcher Building (Bldg. 45) on the campus of the National Institutes of Health in Bethesda, Maryland. (Take Metro Red Line to Medical Center.)

Goals: Review and synthesize data on transplacental toxicity of AZT, including two recent studies in mice, to assist the NIH in formulating basic and clinical research plans to address the issues presented, and in determining what additional information should be given to women and their health care providers.

Background: AZT given to pregnant HIV-infected women and their newborns according to the dose and schedule recommended by the U.S. Public Health Service has dramatically reduced the incidence of perinatally acquired HIV infection in the United States. The recommendations also stress the need for careful, long-term follow-up of the treated infants, especially since the long-term effects of AZT are unknown.

Scientists at the National Institutes of Health recently became aware of new data from two studies regarding transplacental carcinogenicity and dose-related effects of the drug zidovudine (AZT) in mice. These studies differ significantly in design and, and not unexpectedly, arrive at different conclusions. One study, done by scientists at the National Cancer Institute, was designed to maximize the potential to demonstrate a carcinogenic effect if it exists. The second study, by investigators at Glaxo-Wellcome, was designed to examine long-term outcomes in mice receiving AZT administered over longer periods of time and at blood levels that parallel those seen in HIV-infected pregnant women taking AZT according to accepted treatment guidelines. The relationship between the regimens used in mouse studies and in people is extremely complex. In fact, scientists know very little about the sensitivity or reliability of the mouse model system in predicting transplacental carcinogenicity in humans.

Scientists and ethicists from NIH, other PHS agencies, academia and the pharmaceutical company met several times in December to examine these data. They concluded that the significance and clinical implications, if any, remain unclear and no immediate changes in public health policy or treatment guidelines are warranted. Continued vigilance in the active follow-up of all treated infants, which has always been standard practice, should continue.

They also concluded that, because of the technical complexities of the study designs and the difficulties in interpreting these studies, an expert panel should assess the data and advise the NIH on future actions. A distinguished panel of independent scientists, ethicists and community representatives with expertise in pharmacology, carcinogenesis, obstetrics, epidemiology, bioethics and HIV medicine will meet next week. The meeting is open to interested scientists, community members, and scientific press.

For more information: Call the NIAID Office of Communications at 301-496-5717.

CP - Hold for 1/17

PACHA Research Committee - 17-Jan-97 Conference Call - p. 1

TO: PRESIDENTIAL ADVISORY COUNCIL ON HIV AND AIDS
RESEARCH COMMITTEE MEMBERS (Fax Nos.)

- o Jerry Cade (702) 877-5342
- o Debra Fraser-Howse (212) 614-0057
- o Phyllis Greenberger (202) 833-3472
- o R. Scott Hitt (310) 652-9655
- o Ronald Johnson (212) 788-9360
- o Alexandra Levine (213) 764-0060
- o Helen Miramontes (415) 476-6042
- o Sandra Thurman (202) 662-3564
- [o Bruce G. Weniger (404) 639-8616]

CC: ✓ Office of National AIDS Policy (202) 632-1096
o Social & Scientific Systems, Inc. (301) 652-1749

FROM: Bruce G. Weniger Tel: (404) 639-8779 (direct)
Fax: (404) 639-8616
bgw2@npi1.em.cdc.gov

DATE: 10 January 1997

SUBJECT: Friday, 17 January 1997 Conference Call on AIDS
Vaccines

Dear All,

As we scheduled at our meeting in Washington last month, our next vaccine conference call is set for Friday, 17 January 1997, starting at 9:55 am EST (6:55 am PST). The number to call into (1-800-403-1032) and the access code to dial (512853) remains the same from previous calls.

Dr. David Baltimore, Dr. Anthony Fauci, and Dr. Ron Moss confirmed their participation. As we discussed in Washington, this is a "catchup" call which differs from our previous format. If anyone has problems connecting after the call has begun, please contact Jane Sanville at 202-632-1090, or my secretary at 404-639-8256 and relay a message to order additional ports, and then keep trying to connect.

PACHA Research Committee - 17-Jan-97 Conference Call - p. 2

Dr. Moss, of the Immune Response Corporation, is the first informant in our series to request to address the Council, rather than be invited. As his biotechnology company is currently only pursuing a therapeutic vaccine for persons already infected, I explained our focus on preventive vaccines. He promised to provide as much experience and insight into the obstacles and impediments and solutions for that kind of vaccine, and to minimize technical details about the performance of his company's therapeutic product. He also pledged that the opportunity to address the Committee would not be actively announced by his company for public relations purposes. Dr. Moss has provided a written statement to accompany his oral presentation. This is included at the end of the faxed version of this memo.

In addition, but not on the call, Professor Raymond E. Spier, submitted to me a written statement and an editorial to add to our collection in the Committee archives. This, too, is attached at the end of this fax. Dr. Spier is the editor of the journal **Vaccine**, and a professor of microbiology at the University of Surrey, UK. He has experience in virus vaccine production at Merck, Sharpe and Dohme, and since 1973 has been involved in virus vaccine research in the United Kingdom.

SCHEDULE Friday, 17 January 1997
(All times Eastern Standard)

9:55 - 10:00 AM **Committee Housekeeping; Announcements**

10:00 - 10:30 **DAVID BALTIMORE, PhD**

A distinguished molecular biologist with over 500 scientific publications. Discoverer of the reverse transcriptase enzyme/gene for which he was awarded the Nobel Prize in Medicine or Physiology. Former President of Rockefeller University, and now I.R. Cottrell Professor of Molecular Biology and Immunology at MIT. Designated

PACHA Research Committee - 17-Jan-97 Conference Call - p. 3

by NIH to lead a revitalized effort for AIDS vaccines at the agency.

10:30 - 11:00 COMMITTEE INTERNAL DISCUSSION

11:00 - 11:15 DR. RONALD MOSS (8:00 - 8:15 PST)

Medical Director and Senior Director of Medical/Scientific Affairs of the Immune Response Corporation, a biotechnology company founded by the late Jonas Salk which has developed an inactivated partial-virus HIV-1 vaccine for therapeutic use. He is also Assistant Clinical Professor at the School of Medicine of the University of California, San Diego.

11:15 - 11:30 ANTHONY S. FAUCI, MD

(Rescheduled from 4 Dec. due to airline delay.)

Director, National Institute of Allergy and Infectious Disease (NIAID), NIH, and the concurrent Chief of the Laboratory of Immunoregulation, NIAID. A world authority in immunology and diseases affecting the immune system, including HIV. Member of the National Academy of Sciences, the Institute of Medicine, and numerous other prestigious scientific organizations, editorial boards, and professional societies, and recipient of many scientific awards.

11:30 - 11:40 More Committee Housekeeping; Announcements

END OF CALL

ATTACHMENTS (faxed): Dr. Ronald Moss, oral statement text
Dr. Raymond Spier, written statement;
editorial (Vaccine 1995;13:1487)

THE IMMUNE RESPONSE CORPORATION

Incentives and Disincentives for Vaccine Development: A Biotech Perspective

Date:

January 10, 1997

From:

Ronald B. Moss, M.D.

- Whole virus gp120 depleted inactivated HIV-1 antigen in incomplete Freund's adjuvant (Figure 1).
- Contains multiple conserved proteins.
- Product uses HZ321, gag subtype G.
- Presently in Phase I, II, and III clinical trials in US and abroad (Figure 2).
- Positive Impact on immunological and virological markers (Figures 3, 4, 5).

Incentives and Disincentives for Vaccine Development: A Biotech Perspective

- **Disagreement over correlates of protective immunity has impeded expedited efficacy testing of products.**
- **Scientific dogma relating to protection has changed over the years.**
 - » **Ten years ago neutralizing antibody was embraced.**
 - » **Presently CMI (CTL, LP, DTH, β chemokines, T_H1) are believed to be important (Figure 6).**
 - » **β chemokine suppression of HIV is virus subtype independent**
- **Scientific orthodoxy has impeded the development of preventive vaccines and immune based therapies.**
- **Applied research is undervalued.**

Incentives and Disincentives for Vaccine Development: A Biotech Perspective

- **Envelope based HIV-1 vaccines were pursued within government sponsored trials while other empirical approaches have been left to private industry at great cost with little government support.**
- **The company pursuing this whole virus gp120 depleted inactivated immunogen has spent over \$100 million dollars on the development of this product.**
- **An empirical approach which includes many different vaccine designs offers an incentive for companies to produce a prophylactic vaccine.**

Incentives and Disincentives for Vaccine Development: A Biotech Perspective

Manufacturing

- **Large scale manufacturing capability must be considered when evaluating a vaccine candidate.**
 - » **The technical capabilities for manufacturing large scale cGMP quantities of a well characterized, whole killed, gp120 depleted product have been established (Figure 5).**
- **Technical hurdles have been overcome for the large-scale production of this product.**

Incentives and Disincentives for Vaccine Development: A Biotech Perspective

Safety

- **Safety parameters must be determined, with risk/benefit taken into consideration before large scale clinical trials of a preventive vaccine are begun.**
- **A whole gp120 depleted inactivated virus vaccine has been injected into over 1,000 HIV seropositives with no serious treatment related adverse events.**

Incentives and Disincentives for Vaccine Development: A Biotech Perspective

Liability

- **Due to liability concerns many companies have focused mainly on therapies for seropositive patients, rather than vaccine.**
- **An insurance fund sponsored by the Federal Government similar to one for pediatric vaccines could be enacted to encourage companies to pursue development of AIDS vaccines.**

Conclusions

- **A whole killed gp120 depleted HIV product can be manufactured for large-scale testing as a preventive AIDS vaccine.**
- **Should many of the disincentives be addressed, this product could be considered a prime candidate AIDS vaccine for testing.**
- **There is a tremendous public health need for a preventive AIDS vaccine.**






Figure 1.

Figure 2.




Clinical Study 103 **Virologic, Cytologic and Clinical Effects of Immunization** **Treated (T) vs Controls (C)**



RJ Trauger, F Ferre, AE Daigle, FC Jensen, RB Moss, et al., "Effect of Immunization with Inactivated gp120-Depleted Human Immunodeficiency Virus Type 1 (HIV-1) Immunogen on HIV-1 Immunity, Viral DNA, and Percentage of CD4 Cells." *JID* 1994; 169:1256-1264.

Figure 3.


In Vitro Lymphocyte Proliferation to HIV-1 Antigen



Moss, RB, et al., Effect of immunization with an inactivated gp 120 depleted HIV-1 Immunogen (REMUNE™) on β chemokine and cytokine production in subjects with HIV-1 Infection. *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology* (IN PRESS).

Figure 4.

Long Term RANTES Production After Immunization



Moss, RB, et al., Effect of immunization with an inactivated gp 120 depleted HIV-1 Immunogen (REMUNE™) on β chemokine and cytokine production in subjects with HIV-1 Infection. *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology* (IN PRESS).

Figure 5.





Figure 6.

A Strategy For Prophylactic Vaccination Against HIV



Jonas Salk, Peter A. Bretscher, Peter L. Salk, Mario Clerici, and Gene M. Shearer, A Strategy For Prophylactic Vaccination Against HIV. *Science* 1993; 260:1269-1271.

Figure 7.

Position Paper**Approaches to a Vaccine Protective against AIDS.****R.E. Spler****Editor: VACCINE****University of Surrey, Guildford, GU2 5XH, U.K.****6th January, 1997****1. The Background**

The current approaches to the epidemic disease caused by the Human Immunodeficiency Virus (HIV) commonly known as the Acquired Immunodeficiency Syndrome (AIDS) are seriously flawed. They devolve from the approach which contends, that if we know everything about the virus at the atomic level then it will be possible to design and manufacture specific chemical molecules which will uniquely interfere with the virus replicative process without deleterious side-effects to the human host of the virus, and thereby cure or ameliorate the disease. After 10 or so years of such investigations we have more knowledge about the molecular and atomic biology of the HIV than any other human disease causing virus. Such information has, in part, led to the generation of drugs which will inhibit two virus specific enzymes, the reverse transcriptase and the virus protease. At present it would seem that a combination of three such drugs may hold the virus replication at bay and possibly extend the life of those who are currently infected with the HIV. Such a treatment is expected to cost each of the infected individuals some \$9,000/annum.

It is crystal clear that the program which has resulted in the above drugs has been driven by the pharmaceutical industry. Were 1 million AIDS patients to spend \$9,000/annum then that industry would increase its income by \$9billion/annum. It is thus convenient for the pharmaceutical industry to dominate the award systems for the research contracts which have been focused on the AIDS disease. It is also useful for that industry to have the research work divided amongst a large variety of independent laboratories, for under such situations it is impossible for any one laboratory to achieve a commanding patent or intellectual property position. Thirdly, it has to be recognised that the system of research contract awards is woefully inefficient when it comes to measuring its productivity against objective criteria such as a disease cure or preventative. This latter point is obvious when one considers that a high proportion of the more gifted people in the university research sector spend a good deal of their time writing grant applications (a majority of which are turned down), in university administrative and teaching duties and in outside consultancies or writing and reviewing papers. They do not and cannot devote their entire efforts and imagination to any one of the projects they have in hand

and they have deliberately to tailor their project grant applications to what they think that the reviewing committee will wear. Again the time spent in talking with the people on the reviewing committees and the *quid pro quo* lobbying which ensues is also a major expenditure of time. A further impediment which the small university based laboratory has to face is that each of the various requirements for the production and testing of a drug or vaccine is generally not present as a working system in that laboratory, which means that tests have to be set up *ab initio* with all of the unreliability which pertains to such acts. Or, alternatively, the smaller laboratories are thrown into ill-fitting consortia. Again competitive instincts and the need to have priority in credit allocations, when papers are written or presented, can bedevil such arrangements.

In sum, it is clear that industry is pressing strongly for the drug-based approach to the AIDS disease. It is content to see the work divided up between a large number of small operations because they cannot threaten eventual industrial exploitation, as industry alone is capable of putting all the pieces of the jigsaw together. It is for these reasons that the vaccine approach to the AIDS epidemic has been neglected. The expenditure of funds on vaccine research has been less than 5% of the AIDS dedicated research expenditures. And were a successful vaccine developed it could be produced for cents/dose and would provide long-term immunity from one or a few such doses. The potential income from such a vaccine would be insignificant when matched with what can be achieved by a drug-based approach to the disease. But from a societal view-point a vaccine is the most cost-effective approach to dealing with the AIDS epidemic.

Were it accepted that the vaccination approach is the one which should receive the highest priority, then it is also clear that the least expensive and most rapid route to the discovery and development of such a vaccine would be achieved by the establishment of a unit facility which would house under one roof (directorship) all the component facilities which are required for the discovery and development of a vaccine. As can be perceived from the subsequent sections of this Position Paper there are many components to be assembled and linked indissolubly to achieve the common goal. When such a concentration of specialists, unencumbered by the sideline issues of grant applications and university politics, are dedicated to the end of achieving a vaccine protective against AIDS the people of the USA have every right to expect a successful outcome; other routes cannot compete in this regard.

2. The Vaccines

There are potentially four approaches to a vaccine protective against the disease of AIDS based on our current knowledge of what constitutes a successful *virus* vaccine. These are: the whole or part of a killed pathogenic virus; a live attenuated virus; virus-like particles and, if the DNA based influenza vaccine works, plasmid DNA. Each such vaccine type may be manifested in a multitude of actual forms.

3. The Components of a Vaccine Discovery and Development System.

The development, production and evaluation of a virus vaccine requires a suite of facilities into which the various vaccine options can be plugged. Such a suite may consist of the following elements:

- an epidemiology unit
- a virus identification unit
- a virus assay unit (by several methods to give viability as well as quantity)
- a virus production unit at the laboratory scale (requires an associated utility which can produce the cell culture systems in which the virus can be grown)
- a virus production facility at the pilot plant scale (c. 100litre reactors) for the production of test lots of vaccine at putative commercial scales of operation)
- a virus purification unit
- a vaccine formulation unit
- a vaccine assay unit using;
 - physicochemical assays for mass, antigenicity, heterogeneity
 - cell culture assays for *in vitro* neutralisation on more than one cell line
 - immune cell assays *in vitro* (antibody and/or CTL response)
 - small animal assays which for HIV can be sensitised mice (SCID)
 - small primate assays
 - large primate assays
 - target animal assays (humans who are infected; humans who are not infected)
- a biochemical unit to provide characterization data based on new and innovative assay systems; this unit may also generate putative vaccine materials, provide understanding on the way inactivation mechanisms work, examine the stability of the virus and the way it is modified immunogenically when formulated as a vaccine and examine at the biochemical level aspects of virus pathogenesis
- a pathogenesis unit to examine at the organismal and cellular level the life history of the virus and the way it causes disease
- a genetics unit to provide information on genetic changes to the virus and their implications for the production of an effective vaccine

- an immunology unit to devise new tests for virus efficacy for *in vitro* assays, to find correlates for immunogenicity in humans using small animals/primates and to discover how the immune system works with regard to the provision of protection against this class of virus.

There would also be a suite of support units consisting of:

- a computation and statistical unit
- workshop units for equipment innovation and maintenance of existing equipment and facilities
- glassware and equipment clean, prepare and sterilise unit
- stores
- laundry
- medium preparation for cell and bacterial culture
- animal cell culture preparation facility for routine use and assays
- high security laboratory facilities which could handle and process pathogenic viruses which includes complete inactivation of solid, liquid and gaseous wastes
- a virus security unit which would monitor and control activities so as to prevent the vaccine developers becoming infected as well as protecting the outside world from the release of infectious virus (for example; by an infected primate)
- a clinical unit for the administration of the vaccines to humans and the evaluation of their efficacy
- a series of animal holding units in which tests on small non-primate animals, small primates and large primates can be effected
- an information resource centre based on a specialist and fully comprehensive library with electronic links to the web
- an administration and site security facility
- facilities to engage with consultants and outside experts and to hold such meetings of scientific and technical staff as necessitated by the work

4. The Implementation of a Vaccine Discovery and Developmental Facility.

This will entail the creation of a new institute whose sole and principle objective would be the discovery and development of a vaccine protective against AIDS.

- It is clear from the range of activities it is necessary to bring together to generate a new vaccine that such an objective is most effectively served by bringing all the component parts under a single roof on a single site.
- As the primate experiments will constitute a major proportion of the totality of the activities it would be judicious to site the discovery and development operation juxtaposed to an existing and large primate facility.
- In view of the bureaucratic difficulties in transforming an existing research institute into an AIDS vaccine institute it would be advantageous to begin a

- new operation from a green-field site.
- Expenditure of the order of \$300million per annum for over 20 years should be the basis on which the institute is funded. This money should emanate from governmental sources as a redeployment of public funds in the public interest.
- An institute could be designed, built, staffed and functioning, were a clear go-ahead given and finances provided up-front within 12-18 months.
- Final staffing levels would be of the order of 1,000 professional and support staff. (Approximately, \$50,000 per head salary plus \$100,000 overhead per staff member) plus \$150 million for the provision of facilities and experiments in primates and humans) The proportions of the expenditure would change as the site and the experimental program required.
- Industry, in any shape or form, should not be involved with the direction of the work of this institute. It is possible that from time to time there would be spin-off products which could be further developed and commercialised by industry; this should be accomplished by a specialised technology transfer unit either based on in-house personnel or specialist operations from outside.
- It may be that industry would be asked to tender for the production and distribution of the vaccine when such had been well enough defined for the production of the necessary SOPs.
- The work and operation of the institute should be monitored by a special commission of the government from time to time with a remit of determining whether the public monies involved have been well used
- Were the institute to successful in its goal then it could be redirected to another vaccine target (malaria, tuberculosis, schistosomiasis etc) assuming that such vaccines have not already been discovered by then.

5. Further Considerations

While I have made some outline suggestions as to how it is possible to proceed with a project which would yield a vaccine protective against AIDS, I cannot give 100% assurances that the outcome will be successful; I can assert however that it is my firm belief that an operation of this sort would be the quickest and surest way to the objective of a vaccine protective against AIDS; it may even be the least expensive.

BUTTERWORTH
HEINEMANN

0264-410X(95)00160-3

Vaccine, Vol. 13, No. 16, p. 1487, 1995
Elsevier Science Ltd
Printed in Great Britain
0264-410X/95 \$10+0.00

Obituary

Jonas Salk

Born 28 October 1914, New York, NY;
died 23 June 1995, La Jolla, CA

*At death we set down life; after death we set down
what that life was about.*

This journal and Jonas Salk go back to a beginning. In compiling the editorial board in 1982, I was minded to approach Dr Salk with a view to ask him to be a member of the then nascent board. His letter of reply was enthusiastic and positive. Yes, he would be delighted to join, but could we call the journal "Vaccinology"? My long and tedious reply refuting this suggestion touched on the issues that as an "-ology" provided for a study of a subject, the intent I had for the journal was that it was to be an element in the sphere of human progress which involved a prophylactic approach to disease. This would clearly involve more than the study of vaccines but would cover their application and the implications of their dissemination. In my mind's eye there was also the more broadly cast noun "Vaccine", which would provide the kind of umbrella to overarch the various fields implicated in bringing a vaccine into practical and widespread use.

Notwithstanding my rebuttal of his idea, he did respond to my request for a paper which appeared in the second issue of the journal. Twelve years later Jonas agreed to serve on the committee of the newly formed society: the International Society for Vaccines (ISV). During our initial and subsequent meetings, I was willingly drawn into the ambit of his charm and intellect. It is from this vantage point that I now want to commemorate his passing.

When we examine the career history of Jonas Salk, we simultaneously review one of the basic dichotomies of our contemporary society: the seeming rivalry between the empiricists and the theorists. The former take the practical approach and make progress by the trial and error method, the latter create a

model (theory) of the situation and from that model they predict how progress can be made. Of course, the theorists have to revert to empiricism to test out their conceptual constructs, but, no matter, they have engaged in the most worthy of human activities: that of resolving the exterior world to a set of manipulable abstractions. This superficial description of the alternative approaches to a pressing problem does not do justice to the empiricist. While that individual might indeed delve into the practical before a full description of the system is available, such a jump is not taken without as detailed a view of the presently known circumstances as it is possible to achieve. Such a step is taken in the full recognition that a complete description of the system is not at hand, but enough is known, both in terms of the nature of the present system and its relationship to analogous situations from the past, to be able to get on with the job. Should such information ultimately prove inadequate, then further experimentation to derive a more complete concept of a system would be entirely appropriate for the empiricist. Both Jenner and Pasteur got on with the engineering of vaccines to protect individuals against virally caused diseases before the existence of a virus was known. Jonas Salk had a disposition like these giants of the past. His inactivated polio vaccine (successfully field trialled in 1955) antedated by some 30 years the elucidation of the atomic structure of the polio virus by Hogle, Chow and Filman. And yet he was criticized for proceeding with this vaccine on the grounds that he had not done enough (any?) science before he brought out the vaccine. If we are to be continually restrained by the lack of courage of the scientific

establishment before we venture forth with new candidates for vaccines, then the world will be deprived of the benefits that would have accrued and the opportunity to gain knowledge at the most expeditious rate practicable.

Jonas had a sense that the problems of humanity were not to be resolved by a readjustment of the pervasive material entities. His books and conversations return to the nature and condition of man as a foundation for the building of a new and better world. He was not comfortable with the thoughts that we might live in a determined world, rather he preferred to go beyond the properties of matter and explore the realm of possibilities that could exist outside the cause and effect system. In his establishment of the Salk Institute he promoted the serious study of those difficult areas of mind and brain with, no doubt, the intent of coming to a more convincing account of wisdom and preferred behaviour. What could be more worthy? By comparison, the recognition of peers pales into insignificance.

The life of Jonas Salk was marked out by a striving for excellence. He worked tirelessly for the success of his vaccine and, in more recent years, for a vaccine that would prevent the disease of AIDS from erupting in individuals already infected with the HIV. In this search he was guided by the principles he had learned from his previous experiences. Killed viruses can be used to evoke a cell-mediated response to the cells of the immune system. The work was going well and making progress: we owe it to him, his memory and the people infected by disease-causing organisms to bring it to fruition.

I regard it as one of the highlights of my life that I had the privilege of meeting with Jonas during the formation of the ISV. He set light to a beacon to inspire us all to achieve those goals which will result in the improvement of the human condition.

R.E. Spier
School of Biological Sciences,
University of Surrey,
Guildford,
Surrey GU2 5XH,
UK

01/06/97 13:48

202 690 7560

HHS NAPO

639-6130 Veronica

001

01/06/97 08:51

301 994 2541

404-639-4581

Harold Jaffe
Melissa A. Sordyl

Exec. Secretary

703-299-0200

Douglas Richardson - chair

Martha F. Rogers

Anthony Fauci

Fenny Hitchcock
301-402-0443 (Tish)

Bill Paul →

301-496-0357

Panel on Clinical Practices for Treatment of HIV Infection

See 2/3/97
Panel on
Clinical
Practices

In order to effectively plan the logistics for our next Panel meeting scheduled for January 24, 1997; 4:30 p.m. to 8:00 p.m., we need to assess how many Panel members will be in Washington, D.C. from January 22-26 (to attend the Retrovirus Conference.)

Please fill in the following information and fax the completed form to:

TO: Shellie Abramson
Office of HIV/AIDS Policy
FAX: 202-690-7560
PHONE: 202-690-5560

NAME OF PANEL MEMBER: _____

Check one:

I DO _____ I DO NOT _____

plan to be in Washington, D.C. for the 4th. Retrovirus Conference; January 22-26, 1997.

Comments: _____

Sheraton Washington

E X E C U T I V E O F F I C E O F T H E P R E S I D E N T

22-Jan-1997 03:24pm

TO: nbollman@irvine.org@INET

FROM: Daniel C. Montoya
 Domestic Policy Council

CC: Patsy Fleming
CC: Carmena Parris
CC: Ursula Sanville

SUBJECT: Services Conf. Call

I have arranged, through AT&T, the Services Committee Conference Call for Friday, January 31, 1997 at 11:00am EST (2 hour time limit). The Teleconference number is 1-800-432-2188. ONAP is the host and the participant code is 414025.

I will be sending out an e-mail/fax to service committee participants as soon as the time is confirmed with you.

Also, I am working on the agenda and will speak with you about it at the end of this week.

Please let me know about the time.

dcm

Clinton Presidential Records Digital Records Marker

This is not a presidential record. This is used as an administrative marker by the William J. Clinton Presidential Library Staff.

This marker identifies the place of a publication.

Publications have not been scanned in their entirety for the purpose of digitization. To see the full publication please search online or visit the Clinton Presidential Library's Research Room.

Interventions To Prevent HIV Risk Behaviors

NIH Consensus
Development
Conference

February 11-13, 1997

I will attend

2/12 AM.

Please call +
RSVP.

Hold for 2/12

Fax: 301 402-0420

Faxed to 301/402-0420 Attention: Saranda

NIH Consensus Development Conference

Interventions To Prevent HIV Risk Behaviors

February 11-13, 1997
Natcher Conference Center
National Institutes of Health

☒ I will attend.

☐ I cannot attend, but send me the
Consensus Statement on Interventions
To Prevent HIV Risk Behaviors

Attend the 2/12 A.M. Session only

Name	<u>Patricia S. Fleming</u>	
Degree	<u></u>	
Title	<u>Director</u>	
Affiliation	<u>White House Office of AIDS Policy</u>	
Address	<u>750 17th Street, NW</u>	
City, State, Zip	<u>Washington, DC 20503</u>	
Phone	<u>202/632-1090</u>	Fax <u>202/632-1096</u>
e-mail	<u></u>	

Please call 301-770-3153 if you have any disabilities that may require specific aids or services during the conference.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

National Institutes of Health
Bethesda, Maryland 20892

January 2, 1997

Jeffrey Levi
Office of National AIDS Policy, DHHS
750 17th Street, N.W.
Suite 600
Washington, DC 20503

Dear Mr. Levi:

As you may have heard, the National Institutes of Health (NIH) is convening a Consensus Development Conference on Interventions To Prevent HIV Risk Behaviors. The conference will be held on February 11-13, 1997, in the Natcher Conference Center on the NIH Campus in Bethesda, Maryland, and is sponsored by the National Institute of Mental Health and the Office of Medical Applications of Research, NIH. Cosponsors are the National Institute on Drug Abuse, National Institute of Child Health and Human Development, National Institute of Allergy and Infectious Diseases, National Institute on Alcohol Abuse and Alcoholism, National Institute of Nursing Research, Office of AIDS Research, NIH, Centers for Disease Control and Prevention, and the Health Resources and Services Administration.

The enclosed five questions will be the focus of the conference. The agenda for the conference is designed to provide the scientific data needed by a non-Federal, nonadvocacy panel of experts to develop a statement in response to the conference questions. The panel's statement will be presented on the last day of the conference and will be based on the totality of the information presented, both written and oral.

Please note that discussion periods are scheduled as part of the agenda. In the spirit of a town meeting, the audience may question the speakers, and if time permits, present scientific data during these periods. Written material may be submitted at any time during the conference. You will also note that we have allocated time on the second day of the program for concise (3- to 5-minute) presentations from organizations such as yours, that wish to present policy statements relevant to the conference questions. Presentations by individuals representing personal views may be permitted if time allows.

The number of presentations are limited and depend on the number of respondents. Thus, we encourage joint presentations. We are not able to pay travel or other expenses for the individuals presenting in this session. If you wish to make a presentation, please complete the enclosed form and send it with your prepared comments to me by mail or fax by 5:00 p.m. eastern time on **January 24, 1997**. Requests to speak after this time may not be honored. Please send your completed form and prepared testimony to:


Ms. Elsa Bray
Office of Medical Applications of Research
National Institutes of Health
Federal Building, Room 618
7550 Wisconsin Avenue, MSC 9120
Bethesda, MD 20892-9120
fax: (301) 468-2245
phone: (301) 496-1144

January 2, 1997
Page Two

You will receive by return fax a confirmation of our receipt of your request. It is important that you include your phone number and address so that you may be contacted regarding your presentation. Please note a registration flier is enclosed for your convenience which contains detailed information about conference logistics. If you plan to attend the conference, whether or not you plan to make a public presentation, please complete and return the response form. Please note if you have disabilities requiring specific aids or services.

The conference promises to present the latest available information on this important topic and has generated a great deal of interest. The meeting will serve to heighten the attention of the research community in this critical area, and will provide the latest information to medical practitioners and the public. Thank you for your interest and participation.

Sincerely,

A handwritten signature in cursive script, appearing to read "Elsa A. Bray".

Elsa A. Bray
Program Analyst
Office of Medical Applications of Research

Enclosures: Preliminary Agenda
Conference Questions
List of Organizations
Registration Flier

**CONSENSUS DEVELOPMENT CONFERENCE ON
INTERVENTIONS TO PREVENT HIV RISK BEHAVIORS**

12/31/96

**Natcher Conference Center
National Institutes of Health**

February 11–13, 1997

Preliminary Agenda

Tuesday, February 11, 1997

8:30 a.m.	Welcome and Introduction	Steven E. Hyman, M.D. Director, National Institute of Mental Health Ellen Stover, Ph.D. Director, Office on AIDS National Institute of Mental Health
8:45 a.m.	Charge to the Panel	John H. Ferguson, M.D. Director, Office of Medical Applications of Research
8:55 a.m.	Overview of Conference	David Reiss, M.D. Conference and Panel Chairperson
	I. Epidemiology of AIDS and HIV Infection and Risk Behaviors	
9:05 a.m.	Epidemiology of AIDS: National and International Perspective	Helene D. Gayle, M.D., M.P.H.
9:25 a.m.	Epidemiology of HIV-Related Behaviors in Risk Populations	Lynda S. Doll, Ph.D.
9:45 a.m.	Discussion	

Tuesday, February 11, 1997 (continued)

II. Design Issues in AIDS Prevention

10:00 a.m.	Reducing High-Risk HIV Behaviors: An Overview of Effective Approaches	Thomas J. Coates, Ph.D.
10:20 a.m.	Some Principles for Preventing HIV: Rigor and Reality in Study Design	Mervyn Susser, M.B., B.Ch., F.R.C.P.(E.), D.Ph.
10:40 a.m.	Discussion	
11:00 a.m.	Theoretical Models of HIV Prevention	Martin Fishbein, Ph.D.
11:20 a.m.	Consequences of HIV Prevention Interventions and Programs: Spectrum, Selection, and Quality of Outcome Measures	David R. Holtgrave, Ph.D.
11:40 a.m.	Discussion	
12:15 p.m.	Lunch	

III. Interventions To Reduce High-Risk Sexual and Substance Abuse Behaviors

1:30 p.m.	Behavioral Interventions With Gay and Bisexual Men and Youth	Jeffrey A. Kelly, Ph.D.
1:50 p.m.	Behavioral Interventions With Heterosexuals	Mary Jane Rotheram-Borus, Ph.D.
2:10 p.m.	Behavioral Interventions With Women	Anke A. Ehrhardt, Ph.D.
2:30 p.m.	Discussion	

A. Behavioral Interventions With Adolescents

3:00 p.m.	Behavioral Interventions With Heterosexual Adolescents	John B. Jemmott III, Ph.D.
3:30 p.m.	Discussion	
4:30 p.m.	Adjournment until Wednesday	

Wednesday, February 12, 1997

B. Interventions With Substance Abusers

8:30 a.m.	Community Outreach as AIDS Prevention	Richard Needle, Ph.D.
8:50 a.m.	The Role of Needle Exchange Programs in HIV Prevention	David Vlahov, Ph.D.
9:05 a.m.	International Epidemiology of HIV Among Injecting Drug Users	Don C. Des Jarlais, Ph.D.
9:20 a.m.	Drug Abuse Treatment as AIDS Prevention	David Metzger, Ph.D.
9:40 a.m.	Discussion	

IV. International Perspective

10:10 a.m.	International Perspective on AIDS Prevention Research	Michael H. Merson, M.D.
10:35 a.m.	Discussion	
11:10 a.m.	Public Statements	
12:30 p.m.	Adjournment until Thursday	

Thursday, February 13, 1997

9:00 a.m.	Presentation of the Consensus Statement	David Reiss, M.D. Panel and Conference Chairperson
9:30 a.m.	Discussion	
11:00 a.m.	Panel Meets in Executive Session	
1:00 p.m.	Press Conference	
2:00 p.m.	Adjournment	

CONSENSUS DEVELOPMENT CONFERENCE ON INTERVENTIONS TO PREVENT HIV RISK BEHAVIORS

PROPOSED CONSENSUS QUESTIONS

1. How can we identify the behaviors and contexts that place individuals/communities at risk for HIV?
2. What individual-, group-, or community-based methods of intervention reduce behavioral risks? What are the benefits and risks of these procedures?
3. Does a reduction in these behavioral risks lead to a reduction in HIV?
4. How can risk-reduction procedures be effectively implemented? (Consider the following: which procedures are ready for wider implementation; which work, under what conditions, is required for other population settings and what are the necessary adaptations for these settings; and gender and contextual factors that favor successful implementation).
5. What research is most urgently needed?

**CONSENSUS DEVELOPMENT CONFERENCE ON
INTERVENTIONS TO PREVENT HIV RISK BEHAVIORS**

1/3/97

List of Invited Organizations

Academy of Educational Development
1255 23rd Street, NW, Suite 400
Washington, DC 20037

Act-Up Golden Gate
592 Castro Street
San Francisco, CA 94114

AIDS Action Council
1875 Connecticut Avenue, NW, Suite 700
Washington, DC 20009

AIDS National Interfaith Network
1400 Eye Street, NW, Suite 1220
Washington, DC 20005

AIDS Policy Center
918 16th Street, NW, Suite 201
Washington, DC 20006

American Anthropological Association
4350 North Fairfax Drive, Suite 640
Arlington, VA 22203

American Evaluation Association
School of Education
University of North Carolina
1 Greensboro
Greensboro, NC 27412-5001

American Foundation for AIDS Research
733 Third Avenue, 12th Floor
New York, NY 10097

American Psychiatric Association
1400 K Street, NW
Washington, DC 20005

American Psychological Association
Office of AIDS
750 1st Street, NE
Washington, DC 20002-4242

American Psychological Society
1010 Vermont Avenue, NW, Suite 1100
Washington, DC 20005

American Public Health Association
1015 15th Street, NW
Washington, DC 20005

American Society of Addiction Medicine
Arcade Suite 101
4601 North Park Avenue
Chevy Chase, MD 20815

American Sociological Association
Division of Medical Sociology
1722 N Street, NW
Washington, DC 20036

Centers for Disease Control and Prevention
HIV and AIDS Prevention Office
1600 Clifton Road, NE
Mail Stop E44
Atlanta, GA 30333

Gay Men's Health Crisis
129 West 20th Street
New York, NY 10011

Health Resources and Services
Administration
5600 Fishers Lane, Room 9A-39
Rockville, MD 20857

Human Rights Campaign Fund
1101 14th Street, N.W.
Suite 200
Washington, DC 20005

National Advocacy Coalition on
Youth and Sex
1711 Connecticut Avenue, NW, Suite 206
Washington, DC 20009

National Alliance of State and Territorial
AIDS Directors
444 North Capitol Street, NW, Suite 706
Washington, DC 20001

National Association of People with AIDS
1413 K Street, NW, 7th Floor
Washington, DC 20005

National Association of State, Alcohol and
Drug Abuse Directors
444 North Capitol Street, NW, Suite 642
Washington, DC 20001

National Association of State
Mental Health Program Directors
66 Canal Center Plaza, Suite 302
Alexandria, VA 22314

National Black Gay and Lesbian
Leadership Forum
1219 South La Brea Avenue
Los Angeles, CA 90046

National Coalition of Hispanic Health
1501 16th Street, NW
Washington, DC 20036

National Education Association
1201 16th Street, NW
Washington, DC 20036

National Gay & Lesbian Task Force
2320 17th Street
Washington, DC 20009

National Leadership Coalition on AIDS
1400 Eye Street, NW, Suite 1220
Washington, DC 20005

National Minority AIDS Council
1931 13th Street, NW
Washington, DC 20009

National Science Foundation
4201 Wilson Boulevard
Arlington, VA 22203

Office of National AIDS Policy
Department of Health & Human Services
750 17th Street, N.W., Suite 600
Washington, DC 20503

Parents, Families, and Friends of
Lesbians & Gays
1101 14th Street, NW
Washington, DC 20005

Planned Parenthood Federation
810 7th Avenue
New York, NY 10019

Population Association of America
721 Ellsworth Drive, Suite 303
Silver Spring, MD 20910

San Francisco AIDS Foundation
P.O. Box 426182
San Francisco, CA 94142-6182


Society for Cross Cultural Research
School of Psychology
Florida Tech
Melbourne, FL 32901-6988

Society for Scientific Study of Sexuality
P. O. Box 208
Mount Vernon, IA 52314

The Hetrick-Martin Institute
2 Astor Place
New York, NY 10003

Treatment Action Group
239 East 7th Street
New York, NY 10016

Whitman Walker Clinic
1407 S. Street, N.W.
Washington, DC 20009



Social & Scientific Systems
7101 Wisconsin Avenue, Suite 1300
Bethesda, MD 20814

(301) 986-4870 telephone
(301) 913-0351 facsimile

for Patsy

from Daniel

CP: Schedule

FACSIMILE MESSAGE

DATE: January 17, 1997

Pages: 2
(including cover)

TO: Daniel Montoya

FROM: Ann Borlo

MESSAGE:

RE: Prison Issues Committee CONFERENCE CALL NOTICE

The previously scheduled conference call for January 30, 1997 has been moved to Thursday, February 13, 1997. The call will be held at 11 am (eastern) time. The number to dial at 11:00 am is (800) 403-1047, the host code is 803345 and the participant code is 312206 (same as previous call).

Call Sharon
Haiti
→ 130?

Hellie MacLure
6-2014

**Presidential Advisory Council on HIV/AIDS
Conference Call Schedule**

Revised: December 27, 1996
(All times are Eastern Standard)

Discrimination:

(800) 403-2004; CODE: 233051

- 1/7 3 pm - 5 pm

Prison Issues:

(800) 403-1047; CODE: 312206

(Host Landau: 803345)

- 1/16 11 am - 1 pm Post meeting review and progress on tasks and recommendations
- 1/30 11 am - 1 pm Progress on community and federal responses

CP Please
Schedule

CP-Scheduling on calendar 12/97

FAX COVER SHEET
CLINICAL DEVELOPMENT
~~EFFICACY TRIALS~~ BRANCH

**VACCINE AND PREVENTION RESEARCH PROGRAM****DIVISION OF AIDS**SOLAR BLDG., 6003 EXECUTIVE BLVD., RM. 2A-36B

NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES, NIH.

BETHESDA, MD 20892-7620

DATE: 12/24/96TOTAL PAGES 2

(INCLUDING COVER SHEET)

TO: PATSY FLEMINGFAX NUMBER: 202 632 1096

FROM: _____

**OUR FAX NUMBER IS (301) 402-3684. IF YOU HAVE ANY
PROBLEMS, PLEASE, CALL SERENA JACKSON OR
_____ AT (301) 496-6177.**

MESSAGE:



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

National Institutes of Health
Bethesda, Maryland 20892

December 24, 1996


Ms. Paisy Fleming
White House Office of AIDS Policy
750 17th Street, N.W.
Suite 600
Washington, D.C. 20503

Dear Ms. Fleming,

The PHS AIDS Vaccine Research and Development Subgroup meeting will be held on Thursday, February 20, from approximately 1pm to 4pm, in room 1A-1 of the Solar building on Executive Boulevard, in Rockville, Maryland. The meeting will focus on laboratory testing for HIV infection in persons who have received preventative HIV vaccines.

We hope that you will be able to attend. Please contact me at your earliest convenience to inform me if you will be able to participate in the meeting.

Sincerely,


Mary A. Allen, R.N., M.S.N.
Clinical Trials Specialist

Clinical Development Branch
Vaccine and Prevention Research Program
Division of AIDS/NIAID/NIH

Phone: 301-402-2310
Fax: 301-402-3684
Email: mallen@nih.gov

CP

for my Schedule

Feb 24 Mon

Housing Works
6-9 Cocktails

Opening
new

facility NYC

on Calendar
11/13/96

Q

***Patsy Fleming**
Friday November 8, 1996

9:30a Conference Call

9:45a Mtg - Jeff Levi

10:00a Hold for possible full Council conference call

12:00p Margaret - Lunch and quilts

2:00p MTG: Alexander Robinson
#898-0414

3:00p MTG: Paul Kawata, Miguelina Maldonado &
Moises Agosto
#483-6622

4:30p MTG: Jane Silver, Dr. Mathilde Krim
Contact: Beth Jones 331-8600

PHOTOCOPY
PRESERVATION

EXECUTIVE OFFICE OF THE PRESIDENT

23-Jan-1997 04:30pm

TO: Patsy Fleming
FROM: Daniel C. Montoya
Domestic Policy Council
CC: Carmena Parris
SUBJECT: Congressman McDermott meeting

Kirsten Gerstner in Congressman McDermott's office would like to schedule a meeting with you and the Congressman to talk about the Council and International issues.

She can be reached at 225-3106.

(Carmena: Patsy would like the meeting to be here if at all possible.)

*Tuesday -
Feb. 4 @ 10⁰⁰ A*
1/2 Hr. Friday Feb 7
*Wilda chisolem
225-3106*
Mike Williams, Chief of Staff
Kirsten Gerstner, Log. Asst.
Rita Patel, Log. Asst. } *AIDS*

THE WHITE HOUSE
WASHINGTON

JAN 15 1997

BY FAX 202/606-3024

TO: Shelly Smith

FROM: Carmena Parris

The following information is being sent per your request:

The Peace Corps and other Federal agencies require HIV testing for persons to be deployed overseas. This meeting is an opportunity for representatives of those agencies and the Centers for Disease Control to discuss the rationale for each agency's mandatory testing policy in the context of public and personal health.

About the Reception


yes
Accepted 1/31/97

The 1996-97 Harkness Fellows and the 1997 Atlantic Fellowships finalists will be present at the reception and will be wearing color-coded name tags.

The Harkness Fellows have been in the United States since late August 1996 and are in the middle of their fellowship year. Please see the enclosed list.

The Atlantic Fellowships finalists have won through to the last stage of the competition, and are in Washington to attend the final interviews at which this year's Atlantic Fellows will be selected. The interviews take place over the weekend following the reception.

IN HONOUR OF THE ATLANTIC AND HARKNESS FELLOWS,
AND THE WHITE HOUSE FELLOWS



*The British Ambassador
and Lady Kerr*

request the pleasure of the company of

Ms Patricia Fleming & Guest

at a Reception

on Friday 7 February at 6.00-7.30pm

British Embassy

3100 Massachusetts Avenue N.W.

Washington, D.C.

Informal

R.S.V.P.

Sarah

202-588-6513

1996 HARKNESS FELLOWS

United Kingdom

James Buchan, Senior Researcher, Department of Management and Social Sciences, Queen Margaret College, Edinburgh

U.S. Program: "Magnet" Hospitals: Innovation in Workforce Management - Improvement in Quality of Care?

Host Institution: University of Pennsylvania

Robin Davies, Group Marketing Director, Westbury plc

U.S. Program: Methods of Achieving Customer Focus and Managing Innovation in US Manufacturing Companies.

Host Institutions: University of Washington, Seattle *and* The Boeing Company

Aminatta Forna, Producer, The Late Show/BBC-TV

U.S. Program: The Concept of Mothering in Minority Communities

Host Institution: University of California, Berkeley

Satvinder Juss, Barrister at Law, Gray's Inn; Senior Law Lecturer, Public Law and Law of Individual and Minority Rights, University of Westminster

U.S. Program: Approaches to Community Health Care in the US, with particular reference to the Needs of Ethnic Minorities.

Host Institutions: The George Washington University *and* Department of Health and Human Services

John Morrison, Deputy Coordinator of Bosnia Project, British Refugee Council

U.S. Program: Methods of Refugee Settlement in the US. Lessons for UK and European Contingency Planning and Policy.

Host Institution: International Institute of the East Bay, Oakland, CA *and* National Committee on Refugees, Washington, D.C.

Michelle New, Clinical Research Psychologist, Institute of Child Health, University of London

U.S. Program: American Approaches to Treatment for Children in Need with a focus on Child Sexual Abuse.

Host Institutions: University of Washington *and* Harborview Sexual Assault Center, Seattle

Andrew Ridley, Contract Manager HIV/AIDS, Lambeth Southwark Lewisham Health Authority

U.S. Program: Analysis of Community-Led Primary and Secondary HIV/AIDS Prevention Initiatives.

Host Institutions: New York City Department of Health *and* Gay Men's Health Crisis, New York

Heather-Jane Sears, Executive Director of Nursing/Quality, King's Healthcare NHS Trust

U.S. Program: Leadership Through Excellent Communication: Ensuring Organizational Values Change Behavior and Increase Customer/Staff Satisfaction.

Host Institutions: University of California, Berkeley *and* UCSF Medical Center

Darren Shickle, Senior Lecturer, Department of Public Health Medicine, University of Sheffield. Honorary Consultant, Centre for Human Genetics, Sheffield Children's Hospital

U.S. Program: Medical Ethics in the USA: Values, Principles, and Practice.

Host Institution: Johns Hopkins University

United Kingdom(Continued)

James Thompson, Director of the Theatre in Prisons and Probations Center and Visiting Lecturer, Manchester University Drama Department

U.S. Program: Theater as a Means to Develop the Capacities of Young People Involved in Crime and the Communities and Institutions Where They Live.

Host Institution: Lyndon B. Johnson School of Public Affairs, University of Texas, Austin

William Wilson, Senior Principal (Legal), Department of the Environment

U.S. Program: How Best to Achieve Results in Environmental Law: Enforcement and Some Alternatives.

Host Institution: Northwestern School of Law of Lewis & Clark College, Portland, OR

Australia

Lindie Clark, Ph.D. candidate, Macquarie University

U.S. Program: Masters in Public Administration

Host Institution: John F. Kennedy School of Government, Harvard University

Kathryn Graham, Associate to his Honour Justice Deane, High Court of Australia

U.S. Program: LL.M. program

Host Institution: Global Law School, New York University

Anthony Keenan, Senior Officer, Victoria Independent Education Union

U.S. Program: The Governance, Funding, and Management of Community-Based Organizations with an Emphasis on Community-Based AIDS Organizations.

Host Institution: University of California, San Francisco

Peter Salama, Resident Medical Officer, St. Vincent's Hospital

U.S. Program: Masters in Public Health (Health and Human Rights).

Host Institution: Harvard School of Public Health, Harvard University

Christina Slade, Senior Lecturer, Faculty of Communication, University of Canberra

U.S. Program: Reasoning and The Broadcast Media: Developing Critical Responses.

Host Institution: New York University

New Zealand

Andrew Kibblewhite, Manager, The Treasury

U.S. Program: Masters in Business Administration

Host Institution: Graduate School of Business, Stanford University

Margot McLean, Director, Northern Territory Breast Screen (Australia)

U.S. Program: Evaluation of Preventive Health Programs: Focusing on Women from Minority Groups.

Host Institution: Harvard University

FAX*PF - decline - sock
had to decline 12/2**file*Date: November 26, 1996Number of pages including cover sheet: 5**To:**Patricia FlemingPhone: (202) 632-1090Fax phone: (202) 632-1096CC:**From:**Gina SpannLogistics SpecialistPhone: (301) 657-4254Fax phone: (301) 657-4258**REMARKS:**☐ Urgent☒ For your review☐ Reply ASAP☐ Please comment

For your information, following is the Agenda for the Panel on Clinical Practices for Treatment of HIV Infection meeting on December 2 and 3, 1996.

Any questions, please contact Barbara Brady at (202)690-5560.

BETAH Associates, Inc.

7910 Woodmont Avenue, Suite 912,

Bethesda, MD 20814

Panel on Clinical Practices for Treatment of HIV Infection*December 2 and 3, 1996**Loews L'Enfant Plaza Hotel**Washington, D.C.***AGENDA****Monday, December 2****7:30 a.m.**Registration
Continental Breakfast**8:00 a.m.-9:00 a.m.****OPENING PLENARY SESSION****8:00 a.m.*****Welcome***

Eric P. Goosby, M.D.

Mark D. Smith, M.D., M.B.A.

8:10 a.m.***Introduction of the Secretary and Opening Remarks***Jo Ivey Boufford, M.D., Principal Deputy Assistant
Secretary for HealthDonna E. Shalala, Secretary of the
Department of Health and Human Services**8:20 a.m.*****Overview: Process for Development of HIV
Clinical Practices***

Eric P. Goosby, M.D.

8:35 a.m.***Scope of the Panel***

John G. Bartlett, M.D.

Charge to the Panel

Anthony S. Fauci, M.D.

8:45 a.m.***Introduction of the Panel***

Eric P. Goosby, M.D.

9:00 a.m.-12:30 p.m.**KEYNOTE PRESENTATIONS, PLENARY SESSION****9:00 a.m.*****Role of the Department of Health and Human Services***

Eric P. Goosby, M.D.

9:15 a.m.***Government Sponsored Basic Research and Clinical Trials***

Anthony S. Fauci, M.D.

9:35 a.m.***HIV Care Delivery - HIV Specialty Clinic***

John G. Bartlett, M.D.

AGENDA (continued)

- 9:50 a.m. *Epidemiology and the Link Between Prevention and Treatment*
Helene D. Gayle, M.D., M.P.H.
- 10:10 a.m. *Discussion*
led by Anthony S. Fauci, M.D.
- 10:25 a.m.-10:45 a.m. Break
- 10:45 a.m. *Third Party Payers*
Mark D. Smith, M.D., M.P.H.
- 11:00 a.m. *Rand Corporation Involvement*
Samuel Bozzette, M.D.
- 11:15 a.m. *Health Outcomes and Experiences of People Living with HIV Infection*
Mark Harrington
- 11:30 a.m. *Health Outcomes and Experiences of People Living with HIV Infection*
Cornelius Baker
- 11:45 a.m. *Discussion*
led by John G. Bartlett, M.D.
- 12:00 p.m.-1:30 p.m. Lunch
- 1:30 p.m. -4:45 p.m. **CURRENT RECOMMENDATIONS FOR COMBINATION THERAPY AND VIRAL BURDEN**
- 1:30 p.m. *Antiretroviral Therapy for HIV Infection in 1996: Recommendations of an International Panel*
Paul Volberding, M.D.
- 1:45 p.m. **Current Status of the Use of HIV-1 RNA Levels in Clinical Practice**
John Mellors, M.D.
- 2:00 p.m. *NIH Panel to Define Principles of Therapy of HIV Infection*
Mark Feinberg, M.D., Ph.D.

AGENDA (continued)

- 2:15 p.m. *USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with HIV*
Jonathan Kaplan, M.D.
- 2:30 p.m. *Canadian HIV Trials Network: Workshop on Antiretroviral Therapy, October 19-20, 1996*
Anita Rachlis, M.D.
- 2:45 p.m. *Keystone National Policy Dialogue on Establishment of Studies to Optimize Medical Management of HIV Infection*
Lawrence Deyton, M.D.
- 3:00 p.m. *Discussion*
led by Anthony S. Fauci, M.D.
- 3:15 p.m.-3:30 p.m. **Break**
- 3:30 p.m. *Resistance Issues*
Margaret Fischl, M.D.
- 3:45 p.m. *Combination Therapy and Viral Load Testing for Women*
Jean Anderson, M.D.
- 4:00 p.m. *Treatment Challenges in Federal Programs*
Eric P. Goosby, M.D.
- 4:15 p.m. *Barriers to Providing Treatment in Communities of Color*
Wayne Greaves, M.D.
- 4:30 p.m. *Discussion*
led by John G. Bartlett, M.D.
- 4:45 p.m.-5:30 p.m. **INTRODUCTION OF WORK GROUPS**
Anthony F. Fauci, M.D.
- 5:30 p.m.-7:00 p.m. **Reception Hosted by Henry J. Kaiser Family Foundation**
(Dinner on Your Own)

AGENDA (continued)**Tuesday, December 3, 1996****8:00 a.m.-9:00 a.m.****Continental Breakfast***Review of Day One*

John G. Bartlett, M.D.

Instructions to Work Groups

Anthony S. Fauci, M.D.

9:00 a.m.-12:30 p.m.**WORK GROUPS MEET CONCURRENTLY****12:30 p.m.-2:00 p.m.****Working Lunch***Summary of Each Workgroup's Discussions***12:45 p.m.****Work Group I - Acute Retroviral Syndrome****1:05 p.m.****Work Group II - People Living with
Asymptomatic HIV Infection****1:25 p.m.****Work Group III - People Living with
Symptomatic HIV Infection****1:45 p.m.****Discussion**co-led by Anthony S. Fauci, M.D. and
John G. Bartlett, M.D.**2:00 p.m.****CLOSING REMARKS AND ADJOURNMENT**

Eric P. Goosby, M.D.

EXECUTIVE OFFICE OF THE PRESIDENT

14-Nov-1996 10:45am

TO: (See Below)

FROM: Nancy A. Min

SUBJECT: Discussion of OMB Budget Recommendations for VA and HHS

*on calendar
ygs*

Message Creation Date was at 14-NOV-1996 10:45:00

This year's budget process has not allowed the time for the formal Director's reviews involving White House staff that we have done in the past. Therefore, Frank wanted each of the PADS to invite the relevant folks to sit down and review our recommendations for how we would meet the budget targets for the agencies in our portfolios. To do this, I'm inviting you to a meeting next Tuesday, November 19, from 10-11:30 AM. We'll convene in Room 248.

If there is someone else in your office who should be invited (instead of, or in addition to, yourself), or if I have left a relevant White House office off this list, please let me know. Also, please confirm your plans to attend by e-mail or phone to my assistant, Sarah Bianchi, at 55178.

I'll look forward to seeing you next week.

go to Sarah

Distribution:

TO: BENAMI_J
TO: BROSTRÖM_M
TO: FLEMING_P
TO: LEVI_J
TO: ABERNATHY_P
TO: CARNEVALE_J
TO: GIBBONS_J
TO: Barbara Chow
TO: Ernest J. Moniz
TO: Anne E. McGuire

CC: RASCO_C
CC: SPERLING_G
CC: TURMAN_R
CC: Gregory C. Simon
CC: John L. Hilley
CC: M. Jill Gibbons
CC: Kathryn O. Higgins
CC: GIBBONS_J

*PF
Call Ted Bahr*

E X E C U T I V E O F F I C E O F T H E P R E S I D E N T

13-Dec-1996 04:15pm

TO: Patsy Fleming
FROM: Leanne A. Shimabukuro
 Domestic Policy Council

6-5574

Rm 217

SUBJECT: RE: More holiday cards...

The card is much too large to put in the mail and it would get damaged. If you could have someone pick it up or if you will be by some other day next week, I would be happy to coordinate with you.

Just let me know what works best. Thanks!

E X E C U T I V E O F F I C E O F T H E P R E S I D E N T

13-Dec-1996 07:04pm

TO: Carmena Parris

FROM: Patsy Fleming
AIDS Policy Council

SUBJECT: Holiday Pick-up

Would you ask ADAM to pick this up when he's going over to the
OEOB later in the week? Thanks.

Mia Masten
C-7431
Susan - Tra
5 pages

5573

Circulate
to all staff

EXECUTIVE OFFICE OF THE PRESIDENT

03-Dec-1996 12:53pm

TO: (See Below)
FROM: Wendy J. Einhellig
National Economic Council
SUBJECT: Annual NEC/CEA/DPC Christmas Party

PFV
CP ✓ yes
SD
JS
DM
AA
RS
PM

This years Christmas party will be on December 13th, 4-6pm in the Indian Treaty Room. Any and all who wish to participate may do so by contributing \$10 for themselves plus \$5 for each guest they invite (you can invite as many as you'd like as long as you contribute for them). This money must be paid by COB on December 10th.

We expect to have a laden food and goodies table and a bar for soda and beer manned by the mess (compliments of the monetary contributions we will all make).

Feel free to call me with any questions. Alice Williams and Elizabeth Drye are coordinating for CEA and DPC.

In keeping with the season, we will also be collecting unwrapped new toys and/or canned food at the door to donate to local charities.

Distribution:

TO: Pauline M. Abernathy
TO: S. Lael Brainard
TO: Paul R. Dimond
TO: Chris Dorval
TO: Jason S. Goldberg
TO: Daniel D. Heath
TO: Elgie Holstein
TO: Gay L. Joshlyn
TO: Thomas A. Kalil
TO: Malcolm R. Lee
TO: Sonyia Matthews
TO: Mark J. Mazur
TO: Elaine M. Mitsler
TO: Thomas O'Donnell
TO: Kristen E. Panerali
TO: Dorothy Robyn

Presidential Advisory Council on HIV/AIDS

December 15-17, 1996

Hyatt Regency on Capitol Hill Hotel
Washington, D.C.

AGENDA

Sunday, December 15

10:00am Interim Council Activities/4 Year Goals/Survey
Scott Hitt

11:30 Office of National AIDS Policy Update
Patsy Fleming

12:00pm LUNCH (on your own)

Subcommittee Meetings:
Discrimination Subcommittee Meeting

International Subcommittee Meeting

Prisons Subcommittee Meeting

1:00pm General Council Business
Scott Hitt

3:00 Subcommittee Meetings:
Prevention Subcommittee Meeting
Presenter: Dr. Helene Gayle/CDC

Research Subcommittee Meeting

Services Subcommittee Meeting

7:00 Adjourn

Monday, December 16

- 8:30am General Council Business
 Scott Hitt
- 9:00 Prisons Issues Panel Presentation to Full Council
 Dr. Ken Moritsugu/Bureau of Prisons
 Linda Frank, Ph.D., R.N./Director of AETC, Pennsylvania AIDS
 Cochise Robertson/Blind Faith/Ex-offender HIV Coalition
 Ruth Gordon, Ph.D.
 Jackie Walker/ACLU Prison Project
 Contact: Kathleen Gerus/Patricia Milon
- 10:30 BREAK
- 10:45 General Council Business
- 11:00 Access to Treatment Panel Presentation to Full Council
 Dr. Richard Moore/J. Hopkins Univ/Cost Benefit/Data Analysis
 Dr. Eric Goosby/HHS
 Christine Lubinski/AIDS Action Council/Medicaid-Medicare Issues
 Diana Fortuna/DPC/Return to Work Issues
 Dr. Sam Shaker/HCFR (no presentation/questions only)
 Contact: Nick Bollman
- 12:30pm LUNCH
- 1:30 Subcommittee Meetings:
 Services Subcommittee Meeting (including Native American Issues)

 Research/Prevention Joint Subcommittee Meeting
- 5:00 Adjourn

Tuesday, December 17

8:30am	General Council Business and Leadership Recommendations Scott Hitt
9:00	Services Subcommittee Report
9:30	Research Subcommittee Report
10:00	Prevention Subcommittee Report
10:30	BREAK
10:45	Prison Subcommittee Report
11:00	International Subcommittee Report
11:15	Discrimination Subcommittee Report
11:30	New recommendations
12:00pm	LUNCH
1:15	New Business/Process Issues/Schedule Next Meeting
3:00	Adjourn

Keith Boykin & Sabrina Sojourner Invite You To

A Holiday Party

Thursday, December 19, 1996

from 7 to 10 p.m.

The National Black Lesbian & Gay Leadership Forum

1436 U Street, NW, #200

Washington, DC 20009

(202) 483-6786

RSVP by December 18, 1996

Dec 1996
w/ Keith Boykin
12/10/96
C



NATIONAL BLACK LESBIAN AND GAY LEADERSHIP FORUM POSITIONS AVAILABLE

The National Black Lesbian and Gay Leadership Forum is seeking qualified, highly-motivated volunteers to staff its new Washington office. Yes, a volunteer staff! This innovative new approach will provide experienced volunteers with a high level of responsibility for 12-month positions, as the Forum grows in Washington.

RESPONSIBILITIES

Each person will report directly to the Executive Director. Persons hired will be expected to participate in occasional staff meetings at the Forum office, but may complete most other tasks away from the office. Staff members will submit brief, monthly written reports and will maintain all work-related files in the Forum's office for future use. All applicants should be available to work 5-10 hours per week. Positions are available starting in January of 1997 and ending in December 1997.

BENEFITS

Why work for free? To give back the knowledge and experience that others have given to you. Do you remember feeling alone when you were younger? Maybe you had no one to turn to when you needed support. Do you want to create a more welcoming environment in the black church? Or perhaps you're concerned about the dramatic increase of AIDS in our community. All these concerns can be addressed by building our own institutions to empower our community.

If you care about these problems, then the Forum provides a fresh new opportunity to lift up the black lesbian and gay community by applying your skills to a critical organization that can use your help. At the same time, you gain new and valuable experience yourself. All approved business-related expenses will be covered by the Forum.

ABOUT THE FORUM

Want to know more about the Forum? The Forum is the only national organization of, by, and for black lesbians and gay men. Our mission is to empower black lesbians and gays by increasing our visibility, building bridges between our communities, and developing leadership skills in our people.

Founded in 1988 in Los Angeles, the Forum runs an AIDS Prevention Team in South Central Los Angeles, an annual national conference that brings together nearly 1000 black lesbians and gay men from across the country, and an annual black men's retreat that instills positive, life-affirming messages in its participants. In addition, we've recently opened our doors in Washington for the first ever Black Lesbian & Gay Community Center, featuring an official community archives, a community conference room, a community calendar to coordinate events, and an open-area reception space available free of charge to local black lesbian and gay organizations.

OTHER WAYS TO HELP

If you don't have the time or desire for a volunteer staff position, there are other ways to help. First, we can use your help as a general volunteer. Second, you can help us find or start community support groups to meet in our office. Third, we are still looking for furniture, equipment, plants and art to furnish the office. Fourth, we can always use your financial support. Contributions, no matter how large or small, are tax deductible. Please call the Forum Office at (202) 483-6786 to learn more.

Now more than ever, we need your support to strengthen our community. Support those who support you!

COMMUNICATIONS COORDINATOR

This person will help oversee all Forum public relations activities and develop communications strategy proposals for the Executive Director. Communications Coordinator will maintain Forum media lists, draft all news releases for Executive Director's approval, and help prepare the Forum's quarterly newsletter.

Experience: Communications Coordinator should have at least 3-5 years of communications or public relations staff experience. Excellent writing skills required. Desktop publishing experience helpful, but not essential. Resume, writing sample, and references required to accompany application.

DEVELOPMENT COORDINATOR

Development Coordinator will research funding sources, draft grant proposals, work with outside advisers, and help develop and implement new fundraising strategies.

Experience: Must have track record of successful nonprofit fundraising. Resume and references required to accompany application.

EVENTS COORDINATOR

Events Coordinator will serve as principal contact for Forum events in Washington, including town meetings, and the Forum's annual Congressional Black Caucus Weekend events and Memorial Day Weekend events. This person will also work closely with the Development Coordinator in preparation of fundraising events and will help develop new events.

Experience: Resume and references required to accompany application.

FIELD COORDINATORS

Field Coordinators will serve as a liaison between the Forum and its affiliates and other local community organizations throughout the nation and will act as an assistant to the Field Director. The Field Coordinators will assist in the development of the annual national resource directory of black lesbian and gay organizations, businesses, and services. Field Coordinators will also help administer the Forum's new grant application process for community based organizations who apply for funding from the Forum.

Experience: Resume and references required to accompany application.

INTERNET WEBSITE COORDINATOR

The Information Systems Coordinator will help maintain the Forum's website, updating it weekly with new information, designing creative new material, and working closely with the Communications Coordinator for new information to include. This person will also help publish the Forum's newsletter.

Experience: Must have experience with the Internet and with websites. Resume and references required to accompany application.

PUBLIC POLICY COORDINATOR

This person will monitor significant federal, state, and local public policy activity and recommend action for the Forum, including positions to be taken.

Experience: Knowledge of federal and local politics required. Lobbying experience on Capitol Hill desirable. Strong interest in current events and background in lesbian and gay issues expected. Resume and references required to accompany application.

VOLUNTEER COORDINATOR

This person will recruit, train, and manage new volunteers. Volunteer Coordinator will seek out students at local colleges and other interested members of the community for assistance.

Experience: Good organizational skills, positive attitude and wonderful interpersonal skills essential. Resume and references required to accompany application.

APPLICATION

(Please attach a resume with this application)

Name _____ Address _____

City/State/Zip _____

Phone Number _____ Fax Number _____ Email _____

List Positions Applying for in Order of Preference

1 _____ 2 _____

3 _____ 4 _____

ANSWER THE FOLLOWING QUESTIONS ON A SEPARATE SHEET OF PAPER. (Please limit your responses to 250 words per question).

1. Please explain your interest in the Forum.
2. Please explain your interest in the positions you selected.
3. Please provide any relevant additional information that is not included in your resume or this application.



AMERICAN UNIVERSITY

W A S H I N G T O N , D C

FAX

*Declined
on voice mail
11/19/96*

To: Carmena Parris, Office of National AIDS Policy

Fax: 202.632.1096

From: Chris Geidner, Director, Students for Healthy Decisions; American University

RG

Fax: 202.885.3396

Re: AIDS Policy Forum

Date: November 13, 1996

Number of Pages to follow: 2

We would love to see Ms. Fleming attend the American University AIDS Awareness Week AIDS Policy Forum to be held on Thursday, December 5, 1996 at 8:30pm. There are several reasons why Ms. Fleming would be an essential and interesting part of this Forum. The Forum will be consisting of two Congressional leaders, one Republican and one Democrat, one AIDS activist, and, hopefully one representative from the Administration. Daniel Zingale, who has accepted the position of Executive Director for AIDS Action, will be representing the AIDS activist community, and Representative Barney Frank who has been invited to represent the Democratic legislators, has expressed great interest in attending. Ms. Fleming would represent the Administration, and is in a position in regards to AIDS policy of equal stature to Mr. Zingale and Mr. Frank.

Thank you for your time, and I would also love to see you attend the Forum. So that you can see where the Forum fits into the week, I have included a tentative schedule of events for AIDS Awareness Week. Should you need any more information, please contact me at 202.885.6429.

OFFICE OF STUDENT ACTIVITIES

4400 MASSACHUSETTS AVENUE, NW WASHINGTON, DC 20016-8118 202-885-3390 FAX: 202-885-3396



AMERICAN UNIVERSITY

W A S H I N G T O N , D C

To: Ms. Patricia Fleming

From: Chris Geidner, Director, Students for Healthy Decisions; American University

Re: AIDS Policy Forum

Date: November 13, 1996

I would like to invite you to attend American University's AIDS Awareness Week AIDS Policy Forum to be held on Thursday, December 5, 1996 at 8:30pm. AIDS Awareness Week is coordinated through Students for Healthy Decisions, American University's health and wellness club. The week consists of a broad range of events, from the AIDS Policy Forum to a Volunteer Fair to a Memorial Vigil.

It was our hope that you could represent the Administration's view on AIDS Policy. The Forum will be a moderated, 90-minute panel bringing together AIDS activist and appointed Executive Director of AIDS Action Council, Daniel Zingale, Congressional leaders from both the Democratic and Republican side of the House, including Representative Barney Frank, who has expressed interest in attending, and hopefully, yourself. The forum would begin at 8:30pm and last until approximately 10:00pm. There will also be a speakers' reception immediately before or after the Forum, depending upon speaker availability.

We feel that you would bring a unique and important view to the Forum. Having seen you speak at the press conference for the *Youth and HIV/AIDS: An American Agenda* Report to the President, I feel that you possess a passionate approach toward dealing with the pandemic, and would love to see that represented at the Forum.

Thank you very much for your time, and I look forward to seeing you on December 5th. Should you have any questions about the Forum or AIDS Awareness Week at American University, please call me at 202.885.6429.

OFFICE OF STUDENT ACTIVITIES

4400 MASSACHUSETTS AVENUE, NW WASHINGTON, DC 20016-8118 202-885-3390 FAX: 202-885-3396



AMERICAN UNIVERSITY

W A S H I N G T O N , D C

STUDENTS FOR HEALTHY DECISIONS

AIDS Awareness Week American University December 1-6, 1996

*Thanks for your
help. Chris*

On Sunday, December 1, the nation and world will commemorate those lost to the AIDS pandemic. World AIDS Day, as it has come to be known, has evolved into AIDS Awareness Week at American University. This week is being coordinated by Students for Healthy Decisions. If you have any questions, please contact Jonathan Russell or Chris Geidner at 202.885.6429.

The week's events include an informational display in the Mary Graydon Center lobby throughout the week, with each day focusing on a different aspect of the pandemic, as well as displays in the residence halls.

Monday will begin the week's events with "A Day Without Art," a program in which all of the artwork in Mary Graydon Center is covered to represent the great loss of AIDS. On Monday evening AU will be teaming up with the George Washington University to promote AIDS Awareness at the AU-GW basketball game to be held in Bender Arena on American University's campus. After the game, the Residence Hall Association will be hosting a showing of And the Band Played On, an HBO docu-drama which depicts the beginnings of the pandemic.

On Tuesday, AU will be host to over 10 area volunteer organizations whose programs include HIV/AIDS volunteer efforts. The American Political Voice, a debate forum at AU, will be hosting the College Democrats and College Republicans in a discussion of HIV/AIDS policy issues.

Wednesday evening will mark the highlight of the week, the AIDS Memorial Vigil which will be held in Kay Chapel. The Vigil will include personal stories, a keynote speaker, and a candle-lighting ceremony.

A Campus Health Fair focusing on AIDS issues will be held in Mary Graydon Center on Thursday to provide clubs, organizations, and departments on campus with the opportunity to share their information on the pandemic with students, staff, and faculty. Thursday evening will bring the AIDS Policy Forum, where AIDS activists, politicians, and policy advisors will discuss the policy future of AIDS and PWAs (People with AIDS).

On Friday the week will wind down with one of the most important events. HIV antibody testing will be offered on campus by the DC Agency on HIV/AIDS. Also, that evening RHA will once again sponsor a movie showing. Philadelphia will be shown.

OFFICE OF STUDENT ACTIVITIES

4400 MASSACHUSETTS AVENUE, NW WASHINGTON, DC 20016-8118 202-885-3390 FAX: 202-885-3396



DEPARTMENT OF

NOV 13 1996

Ms. Patsy Fleming
Director, Office of National
750 17th. Street, N.W.
Suite 600
Washington, D.C. 20503

Please schedule
Call & get list of
other invitees

FF - Thanks on calendar
Faxing it to Gay 11/14
C

Office of the Secretary

Assistant Secretary for Health
ce of Public Health and Science
Washington D.C. 20201

Dear Ms. Fleming:

The purpose of this letter is to invite you to participate as a distinguished guest at the first meeting of the *Panel on Clinical Practices for Treatment of HIV Infection*, a unique and exciting public/private sector partnership approach to develop comprehensive guidance for clinical treatment of people living with HIV disease. This collaborative effort is being sponsored by the U.S. Public Health Service and the Henry J. Kaiser Family Foundation, through the leadership of Mark D. Smith, M.D., M.B.A., Executive Vice President. The panel is scheduled to meet December 2 - 3, 1996 at the Loews L'Enfant Plaza Hotel in Washington, D.C.

During the past several months, we have experienced extraordinary progress in the development, testing and licensure of several new therapies for the treatment of people with HIV/AIDS. This has brought a new dimension to the role of antiretroviral drugs and their effect on the progression of HIV. The growing complexities associated with HIV therapy coupled with the rapid licensure of new therapies has resulted in a problematic situation for clinicians treating people with HIV - a growing number of drugs are available from which physicians can choose, but little guidance is available to physicians on the use of these new therapies.

Expert scientific groups have convened to issue guidelines for employing new therapies. While useful in the clinical setting, the guidance thus far is very limited in scope and does not fully encompass the concerns of health payers, insurers, consumers, government and other interested parties. There remains a need to develop comprehensive clinical practices for treatment of people with HIV infection.

The *Panel on Clinical Practices for Treatment of HIV Infection* will be co-chaired by two internationally recognized and highly respected experts in infectious diseases: Anthony S. Fauci, M.D., Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health; and John G. Bartlett, M.D., Professor of Medicine and Chief of Infectious Diseases, Johns Hopkins University School of Medicine. We look forward to your joining us for the initial meeting of the panel because of your outstanding commitment to advancing sound and compassionate public health approaches for treatment and care of persons with HIV.

Page 2

The work of the panel will evolve over the next three years to promulgate an initial set of comprehensive guidelines for clinical application. Specifically, the panel will assess recommendations resulting from the November 13 and 14 meeting of the NIH panel to Define Principles of Therapy of HIV Infection. (The work of the NIH panel will focus on providing an updated summary of available data on new therapies and their effect on the progression of HIV disease, and make recommendations to be used by clinicians in developing guidelines.)

The *Panel on Clinical Practices for Treatment of HIV Infection* will deliberate to develop clinical practices based on consideration of: (1) recommendations from the NIH panel derived from examination of current data; (2) analysis of existing practices; (3) practices of Federal and private HIV clinical experts; and (4) health outcomes and experiences of people living with HIV. The RAND Corporation will assist in this effort by performing a cost analysis of the proposed practices under consideration by this panel.


As part of its work, the panel will be committed to updating the practices on a regular basis to provide current state-of-the-art guidance to clinicians, payers, and patients regarding effective and appropriate treatment for HIV disease.

Due to the short timeframe involved, I would appreciate your response (no substitutes please) to this invitation as soon as possible but no later than cob Friday, November 15, 1996. Please contact our conference specialist, Ms. Gina Spann-Perry at the BETAH Associates on (301) 657-4254 or fax your acceptance to her at (301) 657-4258. 11/14/96
C

An agenda will be forwarded to you in the next two weeks. If you have any questions, please contact Ms. Barbara Brady, Deputy Director, Office of HIV/AIDS Policy on 202-690-5560.

We look forward to your participation in this innovative and exciting endeavor.

Sincerely,



Eric P. Goosby, M.D.

Director,

Office of HIV/AIDS Policy

Office of HIV/AIDS Policy

Office of the Assistant Secretary for Health

U.S. Public Health Service/DHHS

200 Independence Avenue, S.W.

Washington, D.C. 20201

Tel. (202) 690-5560



☐ Room 733-E
Fax (202) 690-6584

☐ Room 730-E
Fax (202) 690-7560

Deliver to:

Patsy Fleming

Fax: 632 1096

Tel: _____

From: _____

Date: 11/13 : _____

This fax contains 2 pages + cover

If transmission problems occur, please call _____

Comments: _____

UNIVERSITY OF CALIFORNIA, SAN FRANCISCO

BERKELEY • DAVIS • IRVINE • LOS ANGELES • RIVERSIDE • SAN DIEGO • SAN FRANCISCO



SANTA BARBARA • SANTA CRUZ

CENTER FOR AIDS PREVENTION STUDIES (CAPS)
University of California, San Francisco (UCSF Box 0886)

74 New Montgomery, Suite 600
San Francisco, CA 94105

Tel: (415) 597-9100
Fax: (415) 597-9213

Nov. 13, 1996

Patricia Fleming
Office of National AIDS Policy
750 17th Street, NW
Washington, DC 20012

Dear Ms. Fleming:

We write to invite you to a meeting to explore new ways to encourage individuals at risk to find out their HIV serostatus.

The challenges are evident. A decade and a half into the epidemic, estimates are that half or more gay men and injection drug users do not know their HIV status. Too many women are still finding out they are infected only when giving birth to an infected child. This ignorance is resulting in squandered treatment opportunities. The study published by Wortley and her colleagues in the journal *AIDS* last year gave perhaps the most stark summary of the problem: a review of more than 2400 people with AIDS in eleven states revealed that 36% were tested for HIV within two months and 51% within one year of their AIDS diagnosis--this, despite the decade that typically lapses between infection and the development of AIDS.

Against this backdrop we face new challenges and opportunities. The advent of combination therapies provides even greater warrant for people to find out their HIV status, and if positive to seek medical care and frequent monitoring. Advances in HIV testing, including home access testing, saliva tests, and viral burden assays, are also propelling changes in how programs to encourage HIV testing are crafted and effectuated.

CAPS and the National Alliance of State and Territorial AIDS Directors (NASTAD) are hosting this meeting with funding from the CDC and support from the White House Office of National AIDS Policy. The National Minority AIDS Council (NMAC) and the National Association of People with AIDS (NAPWA) have also graciously assisted in planning the session. We invite you to join federal, state, and local agency representatives, behavioral scientists, clinicians, representatives from community-based organizations and other key players in an effort to develop new approaches to HIV testing--approaches commensurate with the urgency of the problem described above.

Our meeting will take place in San Francisco at the Marriott Hotel on **Thursday and Friday, December 19 and 20th**. We apologize in advance for the meeting date and for taking you away from your families so close to the holidays. We can only promise you a

on calendar
Dec. 19 & 20
Declined with letter
12/10/96
C

Letter to Ms. Fleming
Date Nov. 12, 1996
Page two

lively meeting, one with an exceedingly practical and useful focus. In part, we will undertake a critical examination of federal programs of HIV testing and counseling--how dollars flow, how programs work and how agencies cooperate. We will also look at the private sector role--the part to be played by clinical caregivers and community-based organizations. Although we will only be meeting once, we hope that the session and a subsequent report on the state of HIV testing and counseling will help catalyze and galvanize further efforts by many of the wider constituencies represented around the table.

Please RSVP by faxing the attached form to CAPS as soon as possible. If you are able to attend, Jeff Stryker from CAPS will be calling you to discuss further details related to your participation. Meanwhile, if you have any logistical questions, please call or e-mail Lulu Chou of CAPS at the numbers on the attached form.

Thank you for your attention. We look forward to seeing you in December.

Regards,

Margaret Chesney
Co-Director
Center for AIDS Prevention Studies

Julie Scofield
Executive Director
National Alliance of State and
Territorial AIDS Directors

Reply Form

HIV Testing and Counseling Meeting

 X I am interested in attending
 I am unavailable to attend

A block of rooms has been reserved. Check below and a room will be held in your name at:

Marriott Hotel
55 Fourth Street, San Francisco, CA 94103
415.896.1600
415.896.6176 (fax)

I need a hotel room on:

 X Wednesday, December 18, 1996
 X Thursday, December 19, 1996
 X Friday, December 20, 1996

Your Name: Patricia S. Fleming

Please fax your response to:

Lulu Chou
Center for AIDS Prevention Studies
Fax: 415.597.9213
NO LATER THAN NOVEMBER 8, 1996

If you have any logistical questions, please contact Lulu
Phone: 415.597.4971
e-mail: lulu_chou@quickmail.ucsf.edu

12/10/96
① Spoke cancelled by Julie
Marriott she said reservations were held under a group by CAB
② left message for Lulu on VM.
C

CAPS

CENTER FOR AIDS PREVENTION STUDIES
UNIVERSITY OF CALIFORNIA SAN FRANCISCO

74 New Montgomery Street, Suite 600
San Francisco, CA 94105

TEL: (415) 597-9100
FAX: (415) 597-9213

www.caps.ucsf.edu/capsweb

Date: Nov 13 96

To: Carmeen Paris

Fax # 202 632 1090 Tel. # 202 632 1096

From: Lulu Chou Tel. # 415 597 4971

Total number of pages (including cover sheet): 4

Enclosed is a letter + reply form
for the testing conference for
Patricia Fleming. I believe I
have already received a reply form
for her. Please call if you have
any questions

If you have questions or problems with this transmission, please call _____

(FAX Code: _____)

EASYLINK 7446326L001 20NOV96 13:58/13:58 EST
FROM: 62029160
AMERICAN EXPRESS TRAVEL
TO: 2026321096

SALES PERSON: 50
CUSTOMER NBR: 1695000023

ITINERARY

TCYTVO

DATE: 20 NOV 96
PAGE: 01

TO: WHITE HOUSE TRAVEL
1600 PENNSYLVANIA AVE
WASH DC 20500

FOR: FLEMING/PATRICIA

12/10/96
Cancelled w/Elizabeth's VM
C

18 DEC 96 - WEDNESDAY

AIR	AMERICAN AIRLINES	FLT:591	COACH
	LV WASHINGTON NATL		153P
	AR DALLAS FT WORTH		429P
	FLEMING/PATRICI	SEAT-13B	
AIR	AMERICAN AIRLINES	FLT:1657	COACH
	LV DALLAS FT WORTH		511P
	AR SAN FRANCISCO		707P
	FLEMING/PATRICI	SEAT-32D	

EQP: SUPER 80
NON-STOP

SNACK/BRUNCH
EQP: BOEING 757
NON-STOP

21 DEC 96 - SATURDAY

AIR	AMERICAN AIRLINES	FLT:1994	COACH
	LV SAN FRANCISCO		936A
	AR DALLAS FT WORTH		257P
	FLEMING/PATRICI	SEAT- 7B	
AIR	AMERICAN AIRLINES	FLT:1252	COACH
	LV DALLAS FT WORTH		342P
	AR WASHINGTON NATL		728P
	FLEMING/PATRICI	SEAT-13B	

LUNCH
EQP: BOEING 767 300
NON-STOP

SNACK/BRUNCH
EQP: SUPER 80
NON-STOP

18 JUL 97 - FRIDAY
OTHER WASHINGTON

CONTINUED ON PAGE 2

SALES PERSON: 50
CUSTOMER NBR: 1695000023

ITINERARY
TCYTVO

DATE: 20 NOV 96
PAGE: 02

TO: WHITE HOUSE TRAVEL
1600 PENNSYLVANIA AVE
WASH DC 20500

FOR: FLEMING/PATRICIA

. TOTAL AIR FARE USD 209.00

. SECURITY ALERT INFORMATION
DUE TO THE FAA MANDATED INCREASE IN AIRPORT SECURITY
YOU MAY BE REQUIRED TO PRODUCE A PHOTO IDENTIFICATION
AT AIRPORT CHECKIN.

FOR AFTER HOUR EMERGENCIES
CALL 800-847-0242/YOUR HOTLINE CODE IS S-KC52

. REMINDER
ALL FREQUENT FLYER BENEFITS EARNED ON OFFICIAL TRAVEL
ARE THE SOLE PROPERTY OF THE U.S. GOVERNMENT AND CANNOT
BE REDEEMED FOR PERSONAL USE.

. ALL UNUSED TICKETS ARE TO BE RETURNED TO AMERICAN
EXPRESS OR YOUR TRAVEL COORDINATOR IMMEDIATELY UPON
RETURN FROM TRAVEL OR WHEN TRIP HAS BEEN CANCELED.

. THANK YOU FOR TRAVELING WITH AMERICAN EXPRESS.



National AIDS Policy Center

For Children, Youth & Families

12/10/94

Patsy:

Thank you for
your efforts to
schedule the meeting
with the Vice-President
on drug abuse issues
for pregnant women
and children. I
understand the meeting
is scheduled for
January 8 at
3:00pm. I will
talk with you

WASHINGTON, DC

about strategy
prior to the
meeting. On behalf
of OPC, Sheri
Satzberg, Mike
Kaiser, MD, me
and Clinton Szeglet, MD
will attend.

Thanks again.

Phil Hargy